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ABSTRACT 
 
 
ERIC J. NORRIS. Hydrogen sulfide modulates hepatic oxygen availability and 
microcirculation during sepsis. (Under the direction of DR. MARK G. CLEMENS) 
 
 
A mismatch between O2 supply and demand leads to the development of tissue hypoxia 
which contributes to hepatic dysfunction and injury during sepsis. Previously, we 
reported that hepatic microcirculatory failure is a major contributor to hypoxia and 
hepatic dysfunction during sepsis. Recent evidence suggests that hepatic H2S levels are 
increased during sepsis. Moreover, the inhibition of endogenous H2S synthesis 
significantly improves survival in septic mice; however, the exact mechanism is not 
known. The present study was designed to investigate the effect of H2S on hepatic O2 
availability and microcirculation during sepsis. We hypothesized that H2S contributes to 
hepatic dysfunction during sepsis by reducing hepatic oxygen availability, via O2 
dependent oxidation of H2S, and by potentiating microvascular dysfunction. We 
demonstrate that the liver is a central regulator of H2S via mitochondrial oxidation during 
sepsis. Additionally, we show that the oxidation of H2S lowers hepatic O2 levels in vivo. 
In the second half of this study, we demonstrate that H2S differentially affects the hepatic 
vascular response to phenylephrine and endothelin-1 which suggests that H2S 
differentially affects presinusoidal and sinusoidal sites in the hepatic microcirculation. 
Using intravital microscopy, we show that portal infusion of H2S is associated with 
sinusoidal constriction and that inhibition H2S synthesis attenuates the sensitization of the 
sinusoids to the constrictor effect of endothelin-1 which improves perfusion. We 
conclude that the contribution of H2S to hepatic tissue hypoxia and microcirculatory 
dysfunction is partially responsible for its detrimental effects during sepsis. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Overview 
 
 Hepatic failure is a significant complication during the late stages of sepsis; 
however, the first signs of hepatocellular dysfunction are observed early during disease 
progression and gradually progress to liver failure [19-20]. In the early stages of sepsis, 
cardiovascular function is characterized by a hyper-dynamic state, consisting of increased 
cardiac output and modest peripheral vasodilation [134]. During this period, overall 
delivery of O2 (DO2) to the liver is increased [27]. Despite the increase in DO2, there is 
ample evidence demonstrating that hepatic injury is due in part to hypoxic stress [13, 28, 
34, 41, 94]. While there is likely a contribution of mitochondrial dysfunction during 
sepsis [32], previous work from our lab and others demonstrate that disturbances in the 
hepatic microcirculation following inflammatory stress are a major contributor to hepatic 
dysfunction [12, 22, 63, 131]. During sepsis, the manifestations of hepatic 
microcirculatory dysfunction include heterogeneous tissue perfusion, focal hypoxia, and 
cell death. Eventually, an inability of the hepatic microcirculation to match O2 supply 
with tissue demand can lead to hepatocellular injury, liver failure and the progression of 
sepsis. 
As opposed to the macrocirculation which is responsible for transporting blood 
between organs, the microcirculation consists of smaller vessels (<100μm) that distribute 
blood within individual tissues. Arterioles are the primary resistance vessels in the 
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microcirculation, and due to their pre-capillary, location are responsible for modulating 
tissue perfusion [80]. Vascular smooth muscle cells (VSMCs) surround arterioles and act 
in functional syncytium in response to various stimuli to contract or relax, leading to a 
change in the vessel lumenal diameter. This change in vascular resistance can increase 
(relaxation) or decrease (contraction) perfusion through the capillaries. Since the 
resistance of a fluid to flow is inversely proportional to the fourth power of the lumenal 
diameter, small changes in vessel diameter can have profound effects on tissue perfusion. 
Originally, it was thought that hepatic portal blood flow was solely regulated by 
total splanchnic drainage and pre-sinusoidal resistance vessels; however, it is now known 
that the hepatic sinusoid is also an important site of hepatic blood flow regulation. During 
sepsis, sinusoidal hyperconstriction results from the hypersensitization of the hepatic 
sinusoid to the vasoconstrictive effect of endothelin-1 (ET-1) [12, 94]. Sinusoidal 
hyperconstriction is associated with heterogeneous blood flow through the sinusoids 
resulting in a mismatch between O2 supply and demand [13]. As a consequence, 
microcirculatory failure contributes to focal hypoxia and organ injury during sepsis.  
The “gasotransmitters”, NO and carbon monoxide (CO), are important 
modulators of the hepatic microcirculation, particularly during sepsis [98, 108]. Recently, 
hydrogen sulfide (H2S) has been added to the class of small, biologically active gases 
known as “gasotransmitters” [135]. It is now established that there are several biological 
functions common between H2S, NO and CO, in particular their ability to cause VSMC 
relaxation and vasodilation [135]. Despite this common feature, the effect of H2S on the 
hepatic oxygenation and microcirculation during sepsis remains unclear. As a vasodilator, 
one would predict that H2S improves hepatic O2 availability and microvascular function 
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following inflammatory stress. In support of this hypothesis, several studies demonstrate 
that H2S provides a protective effect following ischemia/reperfusion injury [54, 73, 116, 
127].  On the contrary, endogenous H2S contributes to disease progression during sepsis 
[5, 144]. Since H2S has been shown to alter cellular O2 levels and modulate vascular 
resistance, the present study was designed to investigate the contribution of H2S to 
hepatic oxygen availability and microvascular dysfunction during sepsis. Overall, we 
hypothesize that H2S is metabolized in the liver at the expense of hepatic O2 availability 
and contributes to hepatic sinusoidal sensitization to ET-1 and tissue hypoxia during 
sepsis.  The findings of this study may provide evidence to partially explain why H2S is 
deleterious during sepsis, despite being protective in several other pathophysiological 
conditions.  
1.2 Hydrogen Sulfide 
H2S is a small, lipophilic gas commonly associated with the characteristic smell 
of rotten eggs. The first reports of a biological effect of H2S predate those of the other 
“gasotransmitters”. Nevertheless, only recently has H2S garnered similar attention as a 
potential mediator in physiological processes [135]. Initial reports documented the 
lethality of exposure to elevated levels of the noxious gas, which was subsequently 
shown to result from potent inhibition of mitochondrial respiration. In a manner similar to 
cyanide poisoning, H2S inhibits the activity of cytochrome c oxidase in the electron 
transport chain thereby preventing proper ATP synthesis [87].  
 For centuries, the toxicity of H2S was the only known physiological effect in 
mammals. H2S was simply considered metabolic waste produced by two pyridoxal 5’ 
phosphate dependent enzymes, cystathionine β synthase (CBS) and cystathionine γ lyase 
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(CSE), during cysteine metabolism [18, 123]. The discovery that other gases act as 
important mediators in mammals led to the hypothesis that endogenous H2S could be 
physiologically relevant. Support for this hypothesis was first provided by Abe and 
coworkers who demonstrated that low concentrations of the H2S donor NaHS facilitated 
long term potentiation in rat hippocampus slices suggesting a function of H2S in the 
nervous system  [1]. A potential role in the cardiovascular system was demonstrated by 
Hosoki et al who reported H2S caused relaxation of isolated aortic rings [48]. The 
observation that CSE -/- mice spontaneously develop hypertension confirmed that 
endogenous H2S is a physiologically relevant mediator [140].  It is now well established 
that endogenous H2S is an important mediator in the nervous, cardiovascular, 
gastrointestinal, pulmonary, and immune systems [136].  
Even though there is a scientific consensus that H2S is endogenously synthesized 
and a physiological important mediator, there is still considerable debate about several 
basic concepts in H2S biology. First and foremost, the biologically active form of H2S is 
not known. H2S is a weak acid in aqueous solution with a pKa1 between 6.6 and 7.1 and 
pKa2 > 12 depending on experimental conditions [136]. Therefore, under physiological 
conditions, H2S is in equilibrium with the deprotonated form, HS-, with negligible 
amounts of S2-. It is possible that H2S, HS-, or both exert biological functions. The 
different chemical properties of each form of sulfide may produce differential effects. For 
instance, the lipophilicity of H2S allows for diffusion mediated movement across lipid 
membranes, whereas HS- is not freely permeable, allowing for the possibility of 
compartmentalization of sulfide. Whether H2S and HS- exert differential effects has yet to 
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be determined. Therefore, as is currently used in H2S biology, the terms H2S and sulfide, 
are used to refer to both H2S and HS-, collectively, in this study [92].  
The physiological concentration of H2S in vivo remains unknown  [92]. Because 
methods to measure H2S levels are still developing, initial reports that identified the 
physiological circulating range to be between 10-300μM appear to be an overestimation 
[92]. Since even the lowest concentrations in this range would produce the characteristic 
rotten egg smell of H2S in exhaled breath and blood, it is likely that circulating plasma 
H2S levels are much lower or H2S is bound in an undetectable form. In preliminary 
experiments, we were unable to detect any H2S immediately after adding it to whole 
blood with the commonly used methylene blue H2S assay. Interestingly, H2S was easily 
detectable when added to plasma alone, suggesting an interaction between red blood cells 
and H2S.  
It is now thought that the level of H2S in vivo is the result of local rates of H2S 
production and disposal, which may be affected during disease states. The primary source 
of H2S in the nervous system is CBS, while CSE is the main source of H2S in the 
cardiovascular system and liver [1, 140]. Recently, a third enzyme, β mercaptopyruvate 
transferase (3MST), has been shown to produce a small amount of H2S; however, the 
functional significance of this enzyme on total H2S levels remains unclear [114]. CSE is 
constitutively expressed in the liver in several different cells including hepatocytes, 
hepatic stellate cells (HSC) and kupffer cells (KC) [33]. In addition, we have observed 
expression of CSE in isolated rat sinusoidal endothelial cells (data not shown). As the 
primary recipient of blood flow, the liver is subjected to a secondary source of H2S from 
bacteria in the GI tract which synthesize H2S as a metabolic byproduct producing H2S 
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concentrations into the millimolar range [15]. This large, potentially toxic amount of 
sulfide is mostly sequestered and disposed in the feces; however, a small portion can 
escape the intestinal epithelial barrier and enter the portal circulation. Due to the 
combination of endogenous and exogenous sources of H2S, it is likely that the liver is 
exposed to elevated levels of H2S, particularly during sepsis. However, how the liver 
disposes of H2S during sepsis remains unclear. 
1.3 Hepatic hydrogen sulfide oxidation and sepsis 
Treatment with bacterial endotoxin (LPS) leads to an increase in CSE expression 
in the macrophage like RAW 246.7 cell line suggesting that H2S levels may increase 
during an inflammatory response [149]. In different in vivo models of sepsis, both cecal 
ligation and puncture and endotoxin treatment cause an increase in hepatic CSE 
expression which resulted in an increased hepatic capacity to synthesize H2S [144]. In 
addition to elevated endogenous H2S levels, damage to the intestinal cells has been 
shown to reduce their ability to detoxify H2S which may permit more diffusion of H2S 
into the portal circulation [129]. Moreover, in preliminary studies, we were able to detect 
measurable amounts of H2S in the peritoneal fluid of rats following CLP supporting the 
hypothesis that there are elevated levels of bacterial derived H2S during peritonitis. 
 Given that oxidative catabolism of toxins in the circulation is a main function of 
the liver, it is possible that the liver has the ability to dispose of H2S to protect itself from 
toxic accumulation and prevent H2S entry into the systemic circulation. Recently, 
Lagoutte et al reported that colonic epithelial cells metabolize H2S via mitochondrial 
oxidation which protects them from toxic levels of sulfide derived from the gut bacteria 
[68]. Early studies on sulfide detoxification show that oxidation of H2S occurs in a 
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recirculating isolated, perfused liver system with a concomitant increase in hepatic O2 
consumption [8]. Accordingly, several studies have demonstrated an inverse relationship 
between O2 and H2S levels in various experimental settings [91, 93, 138]. This led to the 
hypothesis that H2S acts as a cellular oxygen sensor. When O2 levels fall, H2S oxidation 
is inhibited allowing for the accumulation of H2S. At sufficient levels, H2S would exert a 
biological function to raise O2 levels. One possibility would be vasodilation of resistance 
vessels leading to an increase in tissue perfusion which would raise cellular O2 levels. 
Once O2 levels reach adequate levels, H2S oxidation can resume and H2S levels would 
fall [91]. In this scenario, the balance struck between O2 and H2S ensures adequate tissue 
perfusion. However, this scenario may be potentially detrimental in the septic liver.  
During sepsis, impaired O2 delivery and mitochondrial dysfunction leads to 
inefficient ATP production [13, 23]. Any physiological process that consumes hepatic O2 
may contribute to hepatic hypoxic stress. This raises the possibility that hepatic oxidation 
of H2S during sepsis may exacerbate the hepatic tissue hypoxia. On the contrary, if the 
capacity to metabolize H2S is inhibited during sepsis, then H2S may accumulate to toxic 
levels and contribute to hepatic mitochondrial dysfunction via inhibition of cytochrome c 
oxidase. Therefore, the first part of this study was designed to test the capacity of the 
liver to metabolize H2S and to determine if H2S oxidation remains a priority during 
sepsis.  
1.4 H2S and hepatic microcirculation during sepsis  
It is known that failure of the microcirculation is a major contributor to the 
progression of sepsis. Previous work from our lab and others focused on the important 
contribution of NO in both systemic and hepatic microcirculatory dysfunction [47, 95-97, 
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124]. Under normal conditions, resistance vessels respond to local and humoral 
vasoregulators to modulate tissue perfusion. During sepsis, the resistance vessels become 
hyporesponsive to the vasoconstrictive effect of catecholamines due to the excessive 
production of vasodilators. In an isolated, perfused liver, treatment with endotoxin 
attenuates the increase in intrahepatic resistance in response to phenylephrine (PE) [97]. 
This effect was reduced when livers were treated with the nitric oxide synthase (NOS) 
inhibitor L-NG-nitroargininie methyl ester (L-NAME), indicating the important role of 
NO in the hyporesponsiveness to catecholamine signaling. The dysregulation of blood 
flow distribution leads to heterogeneous organ perfusion which contributes to organ 
failure during sepsis [52]. While clinical trials targeting NO production have 
demonstrated a decrease in systemic hypotension, they have failed to significantly 
improve septic patient outcomes [77]. 
The regulation of sinusoidal perfusion is more complex than capillary perfusion in 
other vascular beds. At presinusoidal sites, the resistance of portal terminal venules and 
hepatic arterioles is modulated by the contractility of VSMCs similar to other vascular 
beds. In the liver, the hepatic sinusoid participates in the regulation of tissue perfusion as 
well [11]. Individual sinusoids lack VSMCs; rather they are surrounded by hepatic 
stellate cells (HSCs) [79]. These specialized pericytes can respond to local vasoactive 
agents and modulate sinusoidal resistance [25, 62]. HSC contraction reduces sinusoidal 
diameter and decreases flow through individual sinusoids [146]. As a consequence, 
sinusoidal constriction is characterized by the juxtaposition of constricted and dilated 
sinusoids and heterogeneous sinusoidal flow [57]. 
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ET-1 is a potent 21 amino acid vasoactive peptide which is synthesized by SECs, 
HSCs, and KCs in the liver [106, 139]. The physiological effects of ET-1 are dependent 
on two receptor subtypes, ETA and ETB receptors, which are heterogeneously distributed 
in the liver [42]. HSCs primarily express ETA receptors, while SECs express both ETA 
and ETB receptors [49]. ET-1/ETA interaction primarily mediates vasoconstriction, while 
ET-1/ETB interaction produces both vasoconstriction and vasodilation [10, 46]. 
Importantly, ET-1 levels are elevated following inflammatory stress, including sepsis, 
and are correlated with disease severity [3, 119]. Extensive work from our lab has 
demonstrated the importance of the antagonistic relationship between ET-1 and NO in 
modulating the hepatic microcirculation [98]. 
Zhang et al was the first to demonstrate that sinusoidal constriction in response to 
ET-1 co-localizes with HSCs in vivo [146].  ET-1 and PE both increased hepatic 
resistance and decreased portal inflow; however, only ET-1 had an effect on sinusoidal 
diameter. Moreover, inflammatory stress primes the liver to the vasoconstrictive effect of 
ET-1 [94, 107]. The potentiated response of the hepatic sinusoid to ET-1 leads to 
microcirculatory dysfunction and impaired O2 delivery [12]. Additionally, 
hypersensitization to ET-1 during sepsis is associated with an increase in the 
heterogeneity of sinusoidal perfusion resulting in focal hypoxia and hepatic injury [13].  
Mechanistic studies have demonstrated the importance of eNOS-derived NO from 
SECs in maintaining sinusoidal tone [112]. Under normal conditions, the vasoconstrictive 
effect of ET-1 in HSCs is mitigated by NO produced in SECs [98]. The ET-1/ETB 
interaction increases the activity of eNOS in isolated, sinusoidal endothelial cells and 
maintains tissue oxygenation in vivo [67, 98]. During sepsis, the balance between the 
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vasoregulatory effects of ET-1 is skewed resulting in hypersensitization of the hepatic 
sinusoid to the vasoconstrictive action of ET-1. This imbalance is largely due to an 
impairment of ET-1 stimulated eNOS activation [67]. While there is an increase in the 
ratio of ETB receptors to ETA receptors, an increase in the structural protein caveolin-1 
inhibits eNOS activity and NO bioavailability [113, 119]. The importance of ETB 
receptor activation during sepsis is supported by studies which demonstrate a beneficial 
effect in the hepatic microcirculation of an ETB agonist in LPS-treated animals [98]. 
Moreover, administration of the nitric oxide donor, sodium nitroprusside, improves 
microcirculatory dysfunction following injury suggesting the importance of NO in 
maintaining sinusoidal perfusion [41]. 
In livers isolated from normal and cirrhotic rats, Fiorucci et al demonstrated that 
H2S attenuates the vasoconstrictive effect of norepinephrine (NE) via its actions as a 
vasodilator. Since portal hypertension is a significant complication during cirrhosis and 
fibrosis, the decrease in intrahepatic resistance would be beneficial [33]. Unlike cirrhosis, 
portal hypertension is not a significant complication during sepsis. Rather, impaired O2 
delivery due to sinusoidal hyperconstriction is the major complication in liver injury 
during sepsis. As a vasodilator, one would predict that H2S would mitigate sinusoidal 
constriction. However, sinusoidal constriction is observed in the hepatic microcirculation 
despite elevated H2S levels. Therefore, it is possible that H2S does not act as a vasodilator 
in the hepatic sinusoid.  
H2S-mediated vasodilation is mainly the result of activation of KATP channels 
expressed in VSMCs [148]. KATP channel activation produces hyperpolarization and 
relaxation [103]. H2S would only be beneficial in the liver during sepsis if it acts as a 
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vasodilator on the sinusoids; however, the hepatic sinusoids lack VSMCs.  Therefore, 
H2S may exert a different effect in the sinusoid. Moreover, there are several reports that 
H2S can produce vasoconstriction [74, 76].  If H2S exerts a different effect on 
presinusoidal and sinusoidal sites of regulation, then it would differentially affect the 
vascular responses to site specific vasoactive molecules in an isolated perfused liver. 
Therefore, the second part of this study was designed to investigate the effect of H2S on 
PE and ET-1 infusion during endotoxemia to determine if there is a differential effect of 
H2S at presinusoidal and sinusoidal sites of hepatic blood flow regulation.  
To determine if H2S differentially regulated presinusoidal and sinusoidal sites, we 
used an isolated, perfused liver system. The advantage of this experimental technique is 
that it allows for accurate monitoring of changes in intrahepatic resistance during 
constant flow perfusion. PE acts on VSMC cells in the portal terminal venules, whereas 
ET-1 exerts its effect at sinusoidal and presinusoidal sites. Since endotoxemia produces 
hypersensitization of the sinusoids to ET-1, we can identify the location of an H2S effect 
by comparing the effects of PE and ET-1 infusion. However, since changes in inflow 
pressure correlate to total intrahepatic resistance, we could not directly assess the 
sinusoids.  Moreover, heterogeneous sinusoidal flow is a critical component in the 
development of focal hypoxia and liver injury during sepsis. In vivo microscopy is a more 
laborious technique that allows for the direct visualization of the hepatic 
microvasculature and determination of flow through the sinusoids. Therefore, the last part 
of this study was performed to test the contribution of endogenous H2S to 
hypersensitization of the hepatic sinusoid to ET-1 and hepatic tissue perfusion 
heterogeneity during endotoxemia. 
 
 
  
   
 
 
 
CHAPTER 2: THE LIVER AS A CENTRAL REGULATOR OF HYDROGEN 
SULFIDE 
 
 
2.1 Abstract 
The liver is likely exposed to high levels of H2S from endogenous hepatic 
synthesis and exogenous sources from the gastrointestinal tract. Little is known about the 
consequence of H2S exposure on the liver or hepatic regulation of H2S levels. We 
hypothesized that the liver has a high capacity to metabolize H2S and that H2S oxidation 
is decreased during sepsis; a condition in which hepatic O2 is limited and H2S synthesis is 
increased. Using a non-recirculating isolated and perfused liver system, we demonstrated 
rapid hepatic H2S metabolism up to an infusion concentration of 200μM H2S. H2S 
metabolism was associated with an increase in O2 consumption from a baseline 96.7 ± 
7.6 μmoles O2/min/kg to 109 ± 7.4 μmoles O2/min/kg at an infusion concentration of 150 
μM H2S (P<0.001). Removal of O2 from the perfusate decreased H2S clearance from a 
maximal 97% to only 23%. Livers isolated from rats subjected to cecal ligation and 
puncture (CLP) did not differ significantly from control livers in their capacity to 
metabolize H2S suggesting that H2S oxidation remains a priority during sepsis. To test 
whether H2S induces O2 consumption in vivo, intravital microscopy was utilized to 
monitor the oxygen content in the hepatic microenvironment. Infusion of H2S increased 
the NADH/NAD+ ratio (645 grey scale unit increase, P=0.035) and decreased hepatic O2 
availability visualized with Ru(Phen)32+ (439 grey scale unit increase, P=0.040). We 
conclude that the liver has a high hepatic capacity for H2S metabolism. Moreover, H2S 
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oxidation consumes available oxygen and may exacerbate the tissue hypoxia associated 
with sepsis. 
2.2 Introduction 
For centuries, hydrogen sulfide (H2S) has been known almost exclusively as a 
toxic gas associated with the characteristic smell of rotten eggs. However, recent 
evidence now demonstrates that H2S is an endogenously produced biologically active 
gaseous molecule [135]. Numerous studies have identified H2S as an important mediator 
in several biological systems including neurological, cardiovascular, and gastrointestinal 
systems [15, 29, 122, 140]. The role of H2S in inflammation remains poorly defined [84, 
116, 142-145]. H2S is synthesized during cysteine metabolism via two pyridoxal - 5’-
phosphate dependent enzymes; cystathionine β-synthase (CBS) primarily in the brain and 
cystathionine γ-lyase (CSE) primarily in the vasculature and liver [18, 123]. Additionally, 
the synthesis of H2S by the microflora of the gastrointestinal system provides an 
exogenous source of H2S that may enter the portal circulation [15]. The liver is uniquely 
positioned to be exposed to high levels of H2S; however, how the liver responds to 
elevated hydrogen sulfide levels is unclear. Several studies have observed circulating 
hydrogen sulfide levels between < 1 and 300 μM. Anecdotal evidence suggests that it is 
unlikely that H2S circulates in the blood within this range as neither blood nor expired air 
smell of the characteristic rotten egg odor that would be expected from these levels of 
H2S [92]. Therefore, we propose that the liver, as a consequence of its location, is a key 
regulator of H2S levels by maintaining a high capacity for H2S clearance from the 
circulation 
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 Despite extensive research, sepsis remains a significant clinical problem today 
accounting for 1.3 percent of all hospitalizations [78]. Sepsis is associated with an 
inflammatory cascade resulting in hepatic dysfunction [19]. Failure of the hepatic 
microcirculation results in inadequate perfusion resulting in heterogeneous oxygen 
distribution and tissue hypoxia [12, 121]. Several studies have demonstrated cellular 
metabolism of H2S via oxidation in the mitochondria [8, 68]. The oxidation of H2S during 
sepsis could have detrimental unintended consequences during sepsis as it would 
compete for already limited oxygen resources. Moreover, in the absence of mitochondrial 
oxidation, H2S levels could accumulate to potentially toxic levels in the liver and enter 
the general circulation.  
Currently there is very little of information in the literature regarding the effect of 
H2S on the hepatic microenvironment, particularly during pathological conditions, such 
as sepsis, where oxygen availability is limited and H2S synthesis is increased [144]. The 
role of H2S during sepsis is still unclear and a better understanding is vital for the 
potential development of targeted therapeutic intervention [45] Therefore, the aim of the 
present study was to assess the capacity of the liver to metabolize H2S with particular 
emphasis on the relationship between H2S oxidation and hepatic oxygen availability. The 
study was also designed to investigate whether the capacity for H2S oxidation would be 
greatly decreased during sepsis due to hepatocellular dysfunction and limited oxygen 
availability. The findings of this study highlight the delicate balance between H2S 
clearance and hepatic oxygen availability. 
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2.3 Materials and Methods 
Animals: Male Sprague-Dawley rats (Charles River Laboratories, Fayetteville, 
NC) were housed in a temperature-controlled setting under 12-hour light/dark cycles. 
Rats were maintained on standard rat chow or fasted overnight with free access to water 
depending on experimental conditions. All animal manipulation was in strict adherence 
with National Institutes of Health guidelines and experimental protocols were approved 
by the Institutional Animal Care and Use Committee of the University of North Carolina 
at Charlotte.  
Isolated and perfused liver preparation: Preparation of the non-recirculating liver 
perfusion system followed that of Sugano et al with slight modifications [125]. Briefly, 
rats were anesthetized under light isoflurane. A laparotomy was performed to expose the 
abdominal cavity. Heparin (1000 units/kg body) was injected into the inferior vena cava. 
The portal vein was cannulated and perfused with warm, oxygenated Kreb’s Henseleit 
buffer [NaCl 118.95mM, MgSO4 1.2mM, KH2PO4 1.2 mM, KCl 4.65 mM, NaHCO3 25 
mM, EDTA 0.1 mM, CaCl2 2.5mM, C3H6O3 (lactic acid) 5mM, C3H3O3Na (pyruvic acid) 
1 mM, C6H12O6 (glucose) 5mM, pH= 7.4] [2]. The flow rate was held constant and 
calculated as 16ml/minute/100 grams body weight. The thorax was opened and a cannula 
was inserted into the inferior vena cava to allow for collection and monitoring of the 
effluent. Lastly, the vena cava was ligated above the renal vein to close the system and 
ensure perfusate through the effluent cannulation. The liver was perfused in situ with 
warm, oxygenated Kreb’s buffer for a period of 20 minutes to allow for stabilization. 
Oxygen consumption and temperature were monitored during the stabilization period to 
ensure proper preparation. Only livers that demonstrated stable O2 consumption during 
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the stabilization period were considered satisfactory preparations and used in future 
experiments.     
Na2S preparation: The H2S donor Na2S (Sigma-Aldrich, St. Louis, MO) was used 
in all experiments. Na2S completely dissociates in water to the weak conjugate base S2- 
which combines with available H+ ions to establish an equilibrium between H2S  HS- + 
H+ at physiological pH. It remains unclear which form of H2S is biologically active. For 
clarity, the term H2S will be used to represent all sulfide added to the system from Na2S. 
Na2S was dissolved in the appropriate buffer immediately before use as H2S is a volatile 
gas with a short half life. All standard curves were made at the time of experimental 
collection and all samples were stored in the exact conditions.  
H2S clearance: Following the stabilization period, H2S was infused into the 
influent at a rate of 1% of the of total flow rate resulting in final H2S concentrations 
between 0-500 μM in 50 μM increments. Preliminary experiments demonstrated a rapid 
equilibration H2S concentration in the perfusate. Thus, infusion of H2S lasted for 2.5 
minutes. A 2.5 minute recovery period was used to give ample time to return to baseline. 
Inflow and outflow perfusates were sampled in duplicate 90 seconds after H2S infusion 
began. Samples were immediately transferred into 1.5 ml eppendorf tubes containing 150 
μl of 1% zinc acetate to trap the H2S in solution. All samples were frozen and stored at -
80 Celsius overnight before the H2S assay. 
 For experiments requiring different levels of buffer oxygenation, Kreb’s buffer 
was bubbled with a combination of gases (N2, O2, CO2) to achieve the desired level prior 
to the experiment. Oxygen levels were monitored for a period of 20 minutes to ensure the 
combination of gases resulted in a stable level of oxygenation.  
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Oxygen Monitoring: The oxygen content of the perfusate was monitored using an 
oxygen sensitive cathode connected to an oxygen monitor (YSI Life Sciences, Yellow 
Springs, Ohio). All measurements were recorded continuously using Biopac systems MP 
100 transducer and software (Goleta, CA). Oxygen sensors were calibrated daily with 
distilled H2O bubbled with ambient air. Inflow perfusate oxygen concentration was 
measured immediately prior to and after the experiment. Only experiments where inflow 
oxygen content remained constant throughout the experiment were used. 
Isolated and Perfused Heart Preparation: Surgical preparation was done as 
described in Clemens et al with slight modifications [24]. Briefly, the excised heart was 
quickly transferred to a petri dish containing ice cold Kreb’s buffer. The aorta was 
quickly cannulated and secured into position with suture material. Warm, oxygenated 
Kreb’s buffer was perfused through the heart at a flow rate of 10 ml/min/g tissue. The 
pulmonary artery was cannulated to allow collection of outflow sample. The entire organ 
preparation was suspended inside a temperature-controlled perfusion chamber. A 20 
minute period of stabilization occurred prior to the start of the experiment. Infusion with 
H2S occurred in exactly the same manner as with the isolated liver perfusion 
preparations. 
Phenylephrine Treatment: Livers isolated from 18 hour fasted rats were prepared 
as described. Lactate, pyruvate, and glucose were removed from the Kreb’s buffer for 
assessment of baseline gluconeogenesis. After 20 minute of stabilization, the perfusion 
buffer was switched to buffer containing the gluconeogenic substrates lactate (5mM) and 
pyruvate (1mM) with or without 100 μM H2S. Isolated livers were then stimulated with 
the alpha adrenergic agonist L-phenylephrine (PE) (Sigma-Aldrich, St. Louis, MO). A 
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maximum vasoconstrictor response was observed at a PE infusion concentration of 5 μM. 
This concentration was chosen for comparison of gluconeogenesis and vasoactivity 
between control and the experimental H2S group. 
Gluconeogenesis assessment: Glucose production from isolated perfused livers 
was measured using effluent samples collected and stored at -80oC. The concentration of 
glucose in samples was determined using the colorimetric glucose oxidase and 
peroxidase method (PGO enzymes and dianisidine, Sigma-Aldrich, St. Louis, MO). 
Samples were incubated with the enzyme solutions for 30 minutes at 37oC at and then 
read at 450nm on a Beckman Spectrophotometer. Glucose concentrations were calculated 
from a standard curve of known values.  
H2S assay: 75 μl samples were immediately placed in 150 μl of 1% zinc acetate to 
trap H2S in solution. To this solution, 133 μl of 20 mM N,N- dimethyl-p-
phenylenediamine sulfate (dissolved in 7.2 M HCl) and 133μl 30 mM FeCl3 (dissolved in 
1.2 M HCl) was added and then the solution was vigorously vortexed. After 20 minute 
incubation at room temperature, addition of 300 μl of 10% trichloroacetic acid was 
followed by centrifugation (10,000g, 5 min 4 Celsius) to precipitate proteins. Absorbance 
was measured at 670 nm. H2S levels were calculated against a standard curve. All 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO).  
Polymicrobial sepsis model: Cecal Ligation and puncture was used to induce 
polymicrobial sepsis. Fasted rats were anaesthetized under light isoflurane. A small 
midline incision was made to allow for exteriorization of the cecum. The cecum was 
carefully ligated to ensure unobstructed movement of digested food through the GI tract. 
Double puncture of the cecum was performed using a 22 gauge needle. The cecum was 
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gently squeezed to extrude a small amount of feces into the peritoneal cavity. The cecum 
was carefully placed back into the peritoneal cavity and the incision closed. Animals 
received 15ml of saline subcutaneously after the surgical procedure to prevent 
dehydration. Implantable electronic temperature transponders (Bio Medic Data Systems, 
Seaford, Delaware) were placed subcutaneously to allow periodic monitoring of the 
animal. Sham animals received all surgical manipulations with the exception of ligation 
and puncture of the cecum. 24 hours after surgery was performed the liver was isolated 
and H2S clearance was assessed as previously described.  
Intravital Microscopy: Fasted rats were anaesthetized using sodium pentabarbital 
(50mg/kg) (Lundbeck Inc., Deerfield, IL). The abdominal cavity was opened to expose 
the liver and portal vein. The splenic vein was cannulated to allow for infusion of H2S 
with minimal disruption of portal flow. The external jugular vein was cannulated for 
infusion of the oxygen sensor Tris (1, 10-phenanthroline) ruthenium (II) chloride hydrate 
(Ru(phen)32+ (Sigma-Aldrich, St. Louis) and for administration of booster doses of 
pentabarbital as needed. The left carotid artery was cannulated to monitor mean arterial 
blood pressure (Digi-Med high-pressure analyzer; Micro-Med, Louisville, KY). Heart 
rate and blood O2 saturation were continuously monitored using a MouseOx pulse 
oximeter (Starr Life Sciences, Pittsburgh, PA) to ensure stable preparation. Prepared rats 
were placed on an Olympus Ix70 inverted microscope (Olympus America, Melville, NY). 
Saline was first infused at a rate of 50 μl/minute for 10 minutes to determine the effect of 
infusion on hepatic oxygen distribution. Short acting alpha adrenergic agonist 
phenylephrine (0.15μmoles/min/kg) was infused for ten minutes to ensure proper 
experimental and camera setup. Only rats that responded to PE stimulation with a clear 
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decrease in hepatic O2 levels were considered satisfactory preparations. Saline was 
infused for 20 minutes to allow hepatic oxygen distribution and systemic indicators 
(mean arterial pressure, heart rate, and blood O2 saturation) to return to baseline. H2S was 
infused into the portal circulation at a rate of 2 μmoles/min/kg for 10 minutes to achieve 
an estimated plasma concentration of 200μM. A 10 minute recovery period with saline 
infusion immediately followed H2S infusion.  
 Assessment of oxygen distribution in vivo was performed as previously described [99]. 
The liver was exteriorized onto a glass coverslip to allow for epi-illumination of the 
surface of the left lobe. NADH fluorescence (excitation 366nm, emission 450 nm and 
(Ru(phen)32+)(excitation 480 nm, emission 625 nm) were captured using a Cooke 
Sensicam digital CCD camera (The Cooke Corporation, Romulus, MI) and PTI 
Imagemaster software. All gain, black level, and contrast enhancements were exactly the 
same throughout each experiment.  
Statistical Analysis: The data are presented as means ± standard error (SE). 
Statistical significance was determined using ANOVA or linear regression analysis. The 
Student-Newman-Keuls post hoc test was used when ANOVA analysis detected 
significance. Independent and repeated measures analysis was used where appropriate. 
Data not passing the normality test were log transformed to achieve normality. Statistical 
significance was P < 0.05. 
2.4 Results 
The liver has a high capacity for clearance of H2S: To determine if the liver is 
capable of clearing H2S from the circulation, a non-recirculating isolated and perfused 
liver system was utilized. Livers isolated from rats were perfused with Kreb’s buffer and 
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subjected to increasing infusion concentrations of the H2S donor compound Na2S to 
achieve final perfusate H2S concentrations of 50-500μM. The inflow and outflow 
perfusates were collected and sampled for H2S levels. The H2S clearance ratio (outflow 
perfusate [H2S]/inflow perfusate [H2S]) was used as a measure of the hepatic ability to 
clear H2S at each concentration. Perfusion with Kreb’s buffer alone resulted in 
undetectable levels of H2S in the outflow perfusate indicating no net H2S synthesis 
occurring in the liver (data not shown). Infusion of Na2S resulting in final concentrations 
of 50, 100, 150, and 200 resulted in a near complete ability to clear H2S as indicated by 
97%, 95%, 97%, and 91% clearances respectively (Figure 1). Fifty percent H2S clearance 
was observed at an infusion concentration of 303 ± 28 μM. At H2S perfusate 
concentration greater than 400 μM, an almost complete inhibition of H2S clearance was 
observed (Figure 2). To determine if H2S clearance is a general cellular capability or 
potentially site specific, we employed a non-recirculating isolated and perfused heart 
system to compare to hepatic H2S clearance. Na2S was infused to achieve final perfusate 
concentrations in the physiological relevant range (0-200μM). In isolated hearts, a linear 
correlation exists between the concentration of H2S in the inflow perfusate and outflow 
perfusate (Figure 3, R2=0.979, P<0.001). A linear regression line slope of 1 is expected if 
no H2S is removed from the perfusate. For isolated hearts, the slope of the regression line 
was 0.751 indicating very little removal of H2S from the perfusate by the heart. Linear 
regression analysis from isolated livers had a slope of 0.266 indicating nearly complete 
removal of H2S from the perfusate. Importantly, this slope was not statistically different 
from zero over the physiological range (R2=0.266, P=0.071).  
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Effect of oxygen availability on hydrogen sulfide metabolism: To investigate 
whether H2S is being metabolized by the liver or simply bound and sequestered, inflow 
and outflow perfusate oxygen tension was monitored in isolated and perfused livers. 
Inflow perfusate was oxygenated for 20 minutes prior to experiment resulting in an 
inflow oxygen tension of 593.50 ± 28.47 mmHg. Isolated livers consumed 96.7 ± 7.6 
μmoles O2 / min / kg body weight when perfused with Kreb’s buffer alone. Infusion with 
Na2S resulting in final H2S concentrations of 50, 100, 150 and 200 μM significantly 
increased O2 consumption to 104 ± 7.6 (P<0.001), 107 ± 7.7 (P<0.001), 109 ± 7.4 
(P<0.001) and 105 ± 7.4 (P<0.001) μmoles O2 / min / kg body weight respectively 
(Figure 4). Representative tracings of oxygen consumption at infusion concentrations of 
150, 250, and 350 μM demonstrate the shift from increased O2 consumption to the toxic 
inhibitory effect of H2S on oxidative metabolism. Infusion with 250 μM H2S-induced a 
biphasic response with an initial increase in O2 consumption followed by a dramatic 
decrease in O2 consumption, due to the accumulation of H2S during infusion (Figure 5). 
At pathological H2S concentrations greater than 250 μM, an increasing inhibition of 
oxygen consumption was observed with 02 consumption being 74% of maximal 
consumption at 300μM and 46% of maximal consumption at 500μM. The requirement of 
O2 for H2S metabolism was tested by altering the oxygen content of the perfusate. Kreb’s 
buffer was oxygenated to establish perfusate oxygen partial pressures of 593.50 ± 28.47, 
245.72 ± 38.42, and 21.0 ± 2.52 mmHg O2. Isolated livers perfused with the high oxygen 
content perfusate metabolized 50% of the H2S at an inflow concentration of 303 ± 29.5 
μM. Perfusion with buffer containing approximately 300 mmHg O2 resulted in a 
significant leftward shift in the 50% metabolism point to 221.7 ± 5.84 μM, p<.05 (Figure 
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6). Decreasing the oxygen content to 150 mmHg further lowered the 50% metabolism 
point to 170.0 ± 23.6 μM. An essential role of oxygen availability in H2S metabolism was 
observed as Kreb’s buffer bubbled with 95% N2 / 5% CO2 rendered the liver incapable of 
metabolizing 50% of the H2S at any concentration. At the lowest H2S infusion 
concentration (50μM) only 23% of the infused hydrogen was metabolized by the liver.  
Hydrogen sulfide affects the vascular and metabolic response to phenylephrine: 
Given the rapid metabolism of H2S by the liver, we tested whether H2S was able to exert 
physiological effects on the liver during perfusion. Livers isolated from 18 hour fasted 
rats were treated with the alpha adrenergic agonist phenylephrine (5μM) and 
gluconeogenic substrates lactate (5mM) and pyruvate (1mM). After a 20 minute 
stabilization period with incomplete Kreb’s buffer, isolated livers were perfused with 
complete Kreb’s (addition of lactate and pyruvate) buffer containing phenylephrine. 
Immediately before addition of complete Kreb’s buffer, baseline levels for portal pressure 
(3.96 ± 0.19 mmHg), oxygen consumption (1.824 ± 0.165 μmoles O2 / min / g liver wet 
weight), and glucose production (0.254 ± 0.11 μmoles glucose / min / g liver wet weight) 
were recorded. Addition of complete Kreb’s without phenylephrine did not affect portal 
pressure (data not shown). The addition of phenylephrine increased portal pressure to 9.3 
± 0.6 mmHg (Figure 7). In the presence of 100 μM H2S, the phenylephrine-induced 
increase was significantly attenuated (5.7 ± 0.2 mmHg, P<0.001). The effect of H2S on 
gluconeogenesis was determined by measuring the glucose levels in the outflow 
perfusate. Glucose production increased from baseline (0.254 μmoles / min / g liver wet 
weight) in control to 0.957 ± 0.11 (P<0.001) μmoles / min / g liver wet weight (P<0.001) 
following stimulation with phenylephrine and gluconeogenic substrates (Figure 8). 
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Addition of H2S did not significantly affect the increase in glucose output (1.314 ± 0.26, 
P=.084). Since vascular changes and gluconeogenesis have an effect on oxygen levels, 
the partial pressure of oxygen was measured to determine effects on oxygen 
consumption. Addition of phenylephrine and gluconeogenic substrates resulted in a 28% 
increase in oxygen consumption over baseline (Figure 9, P<0.05). A significantly greater 
increase in oxygen consumption was observed when H2S was combined with 
phenylephrine and substrates (80% over baseline, P=0.005).  
Hydrogen Sulfide metabolism remains a priority during sepsis: Cecal ligation and 
puncture (CLP) was performed to investigate whether hydrogen sulfide metabolism is 
altered during polymicrobial sepsis. Rats were subjected laparotomy followed by double 
puncture CLP with a 22 gauge needle. Sham control rats underwent laparotomy without 
CLP. After 24 hours, isolated livers were perfused with increasing concentrations of H2S 
(50-500 μM). Inflow and outflow perfusates were monitored for H2S levels and oxygen 
tension. Isolated livers from sham and CLP treated rats showed no significant difference 
in hydrogen sulfide clearance or oxygen consumption. Sham and CLP treated livers had 
50% clearance concentrations of 198 ± 6.7 and 196 ± 35 μM respectively (Figure 10). 
Sham treated livers reached a maximal H2S clearance rate of 17.2 ± 1.6 μmoles/ min/ kg 
body weight at an infusion concentration of 132 μM (Figure 11). CLP treated livers had a 
maximal H2S clearance rate of 16.9 ± 1.9 17.2 ± 1.6 μmoles/ min/ kg body weight at an 
infusion concentration of 127 μM. Similarly, the oxygen consumption in sham and CLP 
livers did not differ with an increase O2 consumption at low H2S infusion (<150 μM) 
concentrations and a decrease in oxygen consumption at high H2S levels (>200 μM) 
(Figure 12).  
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H2S oxidation induces hepatic tissue hypoxia in vivo: Experiments using a non-
recirculating isolated and perfused liver system are standard practice for monitoring of 
hepatic function, however they are limited. Kreb’s buffer is a much simpler perfusate 
than blood. Furthermore, non-physiological flow rates are required to provide ample 
oxygenation to the tissue leading to increased shear stress. Therefore, we investigated the 
effect of H2S infusion on hepatic oxygen distribution in vivo using intravital microscopy. 
The splenic vein was cannulated for infusion of H2S directly into the portal circulation for 
minimal disruption of portal flow. The surface of the liver was illuminated in order to 
assess the fluorescence of two separate markers of oxygen availability. An increase in 
NADH fluorescence (excitation 366nm, emission 450 nm) represents in an increase in the 
NADH/NAD+ ratio. Since oxygen is the final electron acceptor in the electron transport 
chain, a loss of O2 would result in an increase in the NADH/NAD+ ratio. As H2S is an 
inhibitor of the electron transport chain, it is possible that it could raise NADH/NAD+ 
independently of available oxygen. Therefore, the oxygen sensor molecule Ru(Phen)32+ 
(excitation 480 nm, emission 625 nm) was used as a direct measurement of oxygen 
distribution. Infusion of saline alone resulted in no change in the mean micrograph grey 
scale level in either NADH or Ru(Phen)32+ fluorescence indicating stable oxygen 
distribution during infusion . When H2S was infused at a predicted final plasma 
concentration of 200 μM, a significant increase in the mean micrograph grey scale level 
was observed in NADH fluorescence (645 grey scale unites, P=0.035, Figure 13) and 
Ru(Phen)32+ (439 grey scale unites, P=0.040, Figure 14) following 10 minutes of H2S 
infusion, indicating that H2S oxidation reduces the PO2 in the hepatic microenvironment.  
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2.5 Discussion 
Originally known for its cytotoxicty and pungent odor, H2S is now recognized, 
along with nitric oxide and carbon monoxide, as the third major gasotransmitter with 
important physiological roles in neurological [29], cardiovascular [3], and gastrointestinal 
function[15]. H2S is synthesized endogenously during cysteine metabolism via two 
pyridoxal - 5’-phosphate dependent enzymes: cystathionine β-synthase (CBS) primarily 
in the brain and cystathionine γ-lyase (CSE) primarily in the vasculature and liver, [18, 
123] resulting in physiological levels of H2S reported to be between < 1 and 300 μM 
[92]. Exogenous H2S is synthesized during the normal cellular metabolism of microflora 
in the gastrointestinal system and may enter the portal circulation [15]. As the major 
recipient of gastrointestinal blood flow, the liver is uniquely positioned to be subject to 
high levels of H2S from a combination of endogenous and exogenous sources. 
Furthermore, H2S synthesis is increased during pathological conditions including sepsis 
[144]. Given that a primary function of the liver is the oxidative metabolism of toxins in 
the circulation, we tested the hypothesis that the liver is a critical site of metabolism of 
H2S from the circulation in an oxygen dependent manner. Additionally, we investigated 
whether hydrogen sulfide metabolism is altered during polymicrobial sepsis; a pathology 
in which H2S levels are increased and limited oxygen availability is a contributing 
factor[121]. 
 The hypothesis that the liver is capable of clearing H2S via oxidation from the 
circulation is not new [8]. However, those experiments were conducted using a blood 
recirculating isolated and perfused liver system over a period of 15 minutes making it 
difficult to discount any possible contribution sequestration by red blood cells on the rate 
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of H2S clearance. Since circulation time in the rat is about 1 minute, we sought to 
measure the capacity of the liver to metabolize hydrogen sulfide dissolved in oxygenated 
Kreb’s buffer during a single pass through an isolated liver. Our findings demonstrate 
that the liver clears virtually all hydrogen sulfide at perfusate concentrations below 
200μM (Figure 1). This ability appears to be constant as the liver was able to clear 
100μM H2S from the perfusate for over an hour in preliminary experiments (data not 
shown); a finding in agreement with the original H2S clearance study.  
 Controversy exists over the physiologically relevant concentrations of circulating 
H2S in blood with values ranging two orders of magnitude [92, 127]. The findings of the 
present study provide strong evidence against the circulation of free sulfide in the general 
circulation. As the recipient of 20% of cardiac output, the liver rapidly clears any H2S 
present in the circulation during a single pass at all but the highest reported physiological 
levels. A significant limitation of the isolated and perfused liver study is the absence of 
red blood cells. It has been suggested that H2S may bind to hemoglobin or be metabolized 
by red blood cells into a physiologically inert form [138]. Therefore, we investigated the 
effect of H2S infusion in vivo using intravital microscopy. Infusion of H2S into the portal 
circulation via the splenic vein resulted in a significant decrease in hepatic oxygen 
content suggesting H2S oxidation. Whether freely circulating or bound, our study 
demonstrates that hydrogen sulfide is rapidly cleared from the circulation during passage 
through the liver; however this clearance consumes available oxygen.  
 A recent study by Lagoutte et al. using isolated colonocytes demonstrated that 
H2S is oxidized by the sulfide quininone reductase enzyme [68]. The study also 
demonstrated the capacity for H2S oxidation from isolated mitochondria from several 
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different organs. Therefore, we sought to investigate whether the ability to metabolize 
hydrogen sulfide differed between organs. Using an isolated and perfused heart, we 
demonstrated that the heart has a very small capacity for H2S oxidation, evidence that 
organ function and cellular environment contributes to the capacity for H2S oxidation. 
Similar results were demonstrated in isolated and perfused kidneys and lungs [8]. Our 
results combined with those of Lagoutte et al indicate that the liver and colonic epithelial 
cells, cell types exposed to high levels of H2S, are specialized for effective clearance of 
H2S.  
 Lagoutte et al. also demonstrated that H2S metabolism is a priority in mammalian 
cell types. Furthermore, oxidation of H2S requires a significant amount of O2 in a dose 
dependent manner. This finding was confirmed in our study. Low concentrations of H2S 
(<200μM) resulted in a significant increase in oxygen consumption. As H2S accumulated 
in the liver at higher doses a biphasic oxygen response was observed with an initial 
increase in oxygen consumption followed by a dramatic inhibition presumably from 
cytochrome oxidase c inhibition [87]. The initial increase in O2 consumption at high 
doses of H2S gradually decreased until an almost complete inhibition of O2 consumption 
was observed at 500μM. It is possible that the increase in oxygen consumption observed 
during infusion of H2S could be a result of the vasodilatory effect of H2S. In order to 
assess the vasodilatory effect portal pressure was monitored throughout infusion of H2S. 
Portal pressure remained stable throughout the entire experiment indicating that H2S has 
little vasodilator contribution in the unstimulated isolated and perfused liver system (Data 
not shown).  
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Oxygen availability in the liver is subject to heterogeneous intralobular O2 
distribution which can be exacerbated during pathophysiological states such as sepsis 
[58]. Therefore, we tested whether alterations in O2 availability affect H2S metabolism. 
O2 availability proved to be a requirement for H2S metabolism as decreasing oxygen 
tension in the buffer resulted in a decreased ability to clear H2S. In an extremely low O2 
environment the liver was almost incapable of clearing H2S. Our findings are in 
agreement with the proposal that H2S is a putative oxygen sensor as the levels of H2S and 
O2 are inversely related [91]. Moreover, a 2008 study by Whitfield et al demonstrated an 
accumulation of H2S during periods of hypoxia that was rapidly reversed in the presence 
of oxygen [138]. Whether this increase in H2S is beneficial or detrimental may rely on the 
specific location and stimulus of the increase. Where an increase in the vasculature would 
lead to the appropriate vasoactive response [93], an increase in H2S in the liver may lead 
to tissue hypoxia and contribute to hepatic injury.  
Due to its rapid oxidation in the liver, the possibility arises that H2S is removed 
from circulation before it is able to exert a physiological effect. To test this possibility, 
isolated livers from fasted rats were stimulated with the alpha adrenergic agonist 
phenylephrine and gluconeogenic substrates, lactate and pyruvate. In agreement with 
other research groups, H2S infusion resulted in an attenuation of the phenylephrine 
constrictor response indicating that H2S was still biologically active [33]. Combined 
treatment with phenylephrine and H2S led to greater O2 consumption than phenylephrine 
alone. This was shown to be independent of gluconeogenesis as H2S did not significantly 
alter phenylephrine-induced increases in gluconeogenesis, an oxygen dependent process 
[23]. Thus, the increase in oxygen consumption with co-treatment with phenylephrine 
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and H2S is most likely a combination of increased hepatic perfusion as well as H2S 
oxidation. 
Hepatocellular dysfunction is known to occur in sepsis [19]. Loss of 
hepatocellular function leads to disease progression, however not all functions are 
affected equally [132]. Furthermore, hepatic oxygen availability during sepsis is 
decreased due to decreased hepatic perfusion resulting from an increased sensitization to 
vasoconstrictive mediators (e.g. ET-1) [12]. The decreased hepatocellular function 
combined with inadequate oxygen supply led us to hypothesize that the ability to 
metabolize H2S would be greatly diminished in livers isolated from septic rats. 
Interestingly, our study demonstrated that metabolism of H2S remains a priority in septic 
rat livers. One possible explanation could be the beneficial effect of constant flow 
perfusion on hepatic function. In an ischemia/reperfusion model, Chun et al demonstrated 
that perfusion at a constant flow maintained perfusion and prevented hepatocellular 
injury whereas constant pressure perfusion did not [22]. It is also important to note that 
these studies were done in the early stage of sepsis, prior to the development of septic 
shock. Our model did not produce any mortality within the 24 hour time period used; 
however, it is likely that some mortality would occur after several days. Importantly, our 
study demonstrates that the liver does not lose the capacity to metabolize H2S during the 
early inflammatory phase of sepsis.  
In summary, the present study demonstrates that the liver has an important role in 
the regulation of H2S levels in the circulation. While the debate continues regarding 
physiologically relevant levels of H2S, we provide evidence that the rapid oxidation of 
H2S during a single passage through the liver maintains low systemic circulating levels of 
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H2S. H2S more likely acts as an auto- and paracrine signaling molecule [92]. However, 
especially during septic peritonitis, production of H2S by intestinal bacteria is likely to 
increase H2S levels in the hepatic portal blood. Excess H2S production is removed from 
the circulation by the liver making it a key regulatory site for H2S levels. The oxidation 
of increased levels of H2S predisposes the liver to periods of tissue hypoxia. As hepatic 
O2 levels drop, the capacity of the liver to metabolize H2S decreases forming a 
detrimental positive feedback loop as more H2S enters via the circulation. We have 
demonstrated that H2S oxidation remains a priority during sepsis. H2S oxidation could be 
especially detrimental during sepsis where increased H2S levels during sepsis could 
exacerbate the limited oxygen available [13]. Tissue hypoxia contributes to hepatic injury 
through increased generation of reactive oxygen species [14, 83]. Additionally, HIF 1 
alpha, a hypoxia-dependent signaling molecule, is pro-inflammatory and may contribute 
to hepatic injury [35, 75]. Ultimately, toxic levels of H2S could lead to inhibition of 
cytochrome c oxidase. Recent studies have suggested a potential therapeutic value to an 
induced suspended state of animation of the cell brought about by H2S presumably 
through cytochrome c oxidase inhibition [16]. Administration of H2S has proven to 
provide therapeutic value in rodent models of ischemia/reperfusion injury [117], 
acetaminophen induced hepatotoxicity [84], and sepsis [117, 122, 144]. The complexity 
of H2S during sepsis cannot be overstated as inhibition of H2S production has proved 
therapeutic as well [144]. These discrepancies may be due to experimental parameters or 
time and dose of administration. Nevertheless, it is evident that H2S has a role in 
pathophysiological states. We propose that the liver is unique in the role H2S plays in 
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pathophysiological states due to the priority given to modulate hydrogen sulfide levels in 
the circulation at the expense of hepatic oxygen availability. 
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Figure 1: Percent removal of H2S from perfusate by isolated and perfused liver. The liver 
was perfused in situ via the portal vein by a flow-controlled, non-recirculating perfusion 
system. The H2S donor Na2S was infused into the inflow perfusate to achieve final 
concentrations of 50-500 μM. Inflow and outflow perfusates were assayed for H2S 
concentrations. The percent of H2S cleared from perfusate is plotted against the 
calculated [H2S] inflow. Data are presented as means ± SEM of four separate 
experiments (N=4). Statistical analysis performed using one way repeated measures 
ANOVA with Student-Newman-Keuls post hoc test. *P<0.001 versus 50 μM.  
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Figure 2: Total removal of H2S from perfusate by isolated and perfused liver. 
The total amount of H2S cleared was determined by calculating the amount of H2S 
removed from the perfusate after a single pass through an isolated liver. Data are 
presented as means ± SEM of three separate experiments (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[H2S] (M) inflow
50 100 150 200 250 300 350 400 450 500

m
o
le
s 
H
2
S
 c
le
a
re
d
 /
 m
in
 /
 k
g
 b
o
d
y
 w
ei
g
h
t
0
5
10
15
20
25
30
35
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Isolated heart shows very limited capacity for H2S clearance. An isolated  
and perfused heart was used for comparison to the liver’s ability to clear H2S from  
perfusate. Both organs were perfused at a constant flow rate with oxygenated Kreb’s 
buffer. H2S donor Na2S was infused as 1% of total portal perfusion flow to achieve final  
perfusate concentrations of 50-200 μM. Inflow and outflow perfusate were  
assayed for H2S concentration. Data are plotted as actual [H2S] (μM) inflow versus  
actual [H2S] (μM) outflow. Linear regression analysis was performed on final perfusate  
concentrations considered physiologically relevant (0-200μM). 
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Figure 4: Hydrogen Sulfide metabolism produces a biphasic oxygen consumption 
 response. Inflow and outflow perfusate oxygen tensions were monitored during infusion  
of increasing H2S concentrations (0-500μM) using an oxygen sensitive electrode.  
The change in oxygen tension in the inflow versus outflow was calculated as the amount  
of μmoles of O2 consumed per minute per kg of body weight. One way repeated  
measures ANOVA was used for statistical analysis. Analysis for physiological  
concentrations (0-200μM) and pathological concentrations (250-500μM) were performed  
independently due to the biphasic response. Data are represented as means ±SEM of  
three separate experiments (N=3). * P<0.01 compared to 0 μM infusion. 
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Figure 5: Individual tracings of biphasic oxygen consumption response to H2S.  
Individual tracings of the 5 minute H2S infusion/ recovery cycle observed at  
Na2S perfusate concentrations of 150, 250, and 350μM. Na2S was infused for a period of 
 2.5 minutes followed by a 2.5 recovery period. The dotted line indicates approximate 
 baseline consumption for each tracing (118 μmoles O2 consumed / min / kg body  
weight).  
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Figure 6: Oxygen availability is a requirement for H2S metabolism at physiological  
concentrations. To produce differential oxygen availability in an isolated liver, Kreb’s  
buffer was continuously bubbled with a mixture of O2, N2, and CO2 to achieve  
approximate final inflow O2 content of 600, 300, 150, and 10 mmHg. Inflow and outflow  
perfusate was collected and sampled for H2S content. Results are plotted as % H2S  
clearance versus calculated [H2S] (μM) inflow. Data are presented as means ± SEM for  
three separate experiments (four in 600mmHg group) (N=3). 
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Figure 7: Hydrogen sulfide attenuates phenylephrine-induced increase in portal  
Pressure. Livers were isolated from rats fasted for 18 hours prior to surgery. Kreb’s  
buffer alone was perfused for 20 min to allow for stabilization and baseline  
determinations followed by addition of phenylephrine (PE) with gluconeogenic substrates  
lactate (5mM) and pyruvate (1mM) in the presence or absence of 100 μM H2S. Data are  
means ± SE of 4 PE experiments and 3 H2S separate experiments (N=4,3). Statistical  
analysis performed using one way repeated measures ANOVA with Student-Newman- 
Keuls post hoc test. * P<0.001 compared to control.  
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Figure 8: Hydrogen sulfide has no effect on stimulation of glucose production by  
Phenylephrine. Livers were isolated from rats fasted for 18 hours prior to surgery.  
Kreb’s buffer alone was perfused for 20 min to allow for stabilization and baseline  
determinations followed by addition of phenylephrine (PE) with gluconeogenic substrates  
lactate (5mM) and pyruvate (1mM) in the presence or absence of 100 μM H2S. Data are  
means ± SE of 4 PE experiments and 3 H2S separate experiments (N=4,3). Statistical  
analysis performed using one way repeated measures ANOVA with Student-Newman- 
Keuls post hoc test. * P<0.001 compared to control. Outflow perfusate samples from  
isolated livers were collected for determination of glucose output. 
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Figure 9: Hydrogen sulfide potentiates the increase in O2 consumption following  
phenylephrine treatment. Livers were isolated from rats fasted for 18 hours prior to  
surgery. Kreb’s buffer alone was perfused for 20 min to allow for stabilization and  
baseline determinations followed by addition of phenylephrine (PE) with gluconeogenic  
substrates lactate (5mM) and pyruvate (1mM) in the presence or absence of 100 μM H2S.  
data are means ± SE of 4 PE experiments and 3 H2S separate experiments (N=4,3).  
Statistical analysis performed using one way repeated measures ANOVA with Student- 
Newman-Keuls post hoc test. * P<0.001 compared to control. Oxygen levels in the 
outflow perfusate were monitored to determine the effect of H2S and phenylephrine on  
oxygen consumption.  
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Figure 10: Cecal ligation and puncture does not affect percent hepatic H2S clearance  
ability. Fasted rats underwent cecal ligation and puncture (CLP). Sham surgery served as  
a control. After 24 hours, livers were isolated and subjected to increasing  
concentrations of H2S (50-500μM). Inflow and outflow perfusate were collected and 
 assayed for H2S content. Data are presented as the percentage of H2S cleared in a  
single pass through the liver. Data are presented as means ± SEM of three separate  
experiments (N=3). 
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Figure 11: Cecal ligation and puncture does not affect total hepatic H2S clearance  
ability. Total H2S clearance was measured from livers isolated from CLP and sham  
animals following infusion of Na2S resulting in H2S perfusate concentrations between 50- 
500μM. The total amount of H2S cleared is plotted against estimated inflow [H2S].  
Data are presented as means ± SEM of three separate experiments (N=3). 
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Figure 12: Cecal ligation and puncture does not affect hepatic O2 consumption. 
Outflow perfusate from isolated livers from Sham and CLP treated rats was continuously 
monitored with an oxygen sensitive probe to determine the effect of H2S on O2 
consumption. Data are presented as means ± SE of three separate experiments (N=3).  
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Figure 13: H2S infusion is associated with an increase in NADH autofluorescence.  
Intravital microscopy was used to assess oxygen distribution in the hepatic  
microenvironment. 10 min saline infusion demonstrated stable oxygen distribution  
before H2S infusion. H2S was infused into the portal circulation for 10 minutes followed  
by a 10 minute saline infusion recovery period. NADH fluorescence (excitation  
366nm, emission 450nm) increases as the ratio of NADH/NAD+ increases and is an  
indirect measure of oxygen availability. Gray scale was converted to pseudocolor with  
blue representing black (low NADH/NAD+) and red representing white  
(high NADH/NAD+). 
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Figure 14: H2S infusion is associated with a decrease in hepatic O2 content.  
Intravital microscopy was used to assess oxygen distribution in the hepatic  
microenvironment. 10 min saline infusion demonstrated stable oxygen distribution  
before H2S infusion. H2S was infused into the portal circulation for 10 minutes followed  
by a 10 minute saline infusion recovery period. Ru(Phen)32+ was infused into the  
circulation to serve as a direct oxygen sensor using intravital microscopy. Ru(Phen)32+  
fluorescence (excitation 480 nm, emission 625nm) increases in the absence of oxygen.  
Grayscale was converted to pseudocolor with blue representing black (high O2) and red  
representing white (low O2). Micrographs (4x objective) of one experiment are  
representative of three individual experiments (N=3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: HYDROGEN SULFIDE DIFFERENTIALLY AFFECTS THE HEPATIC 
VASCULATURE IN RESPONSE TO PHENYLEPHRINE AND ENDOTHELIN-1 
DURING ENDOTOXEMIA 
 
 
3.1 Abstract 
Despite being protective in many disease states, H2S contributes to organ injury in 
sepsis. Like the other gasotransmitters, nitric oxide (NO) and carbon monoxide (CO), 
H2S is a modulator of the microcirculation. Since microcirculatory dysfunction is a main 
cause of organ injury during sepsis, the present study was designed to test the effect of 
H2S on microvascular dysfunction in isolated, perfused livers. In most microcirculatory 
beds, endotoxin activates the endothelium resulting in hyporesponsiveness to 
catecholamines and a derangement in blood flow distribution. We demonstrate that H2S 
treatment attenuates the increase in portal pressure during infusion of the α1adrenergic 
agonist, phenylephrine (PE) (P<0.01). H2S almost completely negated the increase in 
portal pressure in livers isolated from endotoxemic rats. Treatment with an inhibitor of 
endogenous H2S, dl-propargylglycine (PAG), reversed LPS-induced hyporesponsiveness 
to PE. Since hepatic microcirculatory dysfunction is associated with excessive sinusoidal 
vasoconstriction and not dilation, we investigated whether H2S affects ET-1-induced 
vasoconstriction in isolated livers. Contrary to PE treatment, H2S did not affect the 
increase in portal pressure during infusion of ET-1 nor did it attenuate the 
hypersensitization of the liver to ET-1 during endotoxemia. Hepatic resistance in control 
rats was increased by PAG treatment during ET-1 infusion, but this increase was not 
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exacerbated during endotoxemia. We monitored hepatic O2 consumption to assess the 
effect of vascular changes on oxygen consumption following ET-1 treatment. Low dose 
ET-1 infusion caused an increase in hepatic O2 consumption, whereas low dose ET-1 
infusion decreased O2 consumption in endotoxemic livers. Interestingly, while we 
observed no effect of PAG on the vascular response to ET-1 infusion during 
endotoxemia, PAG treatment did maintain O2 suggesting a more complex effect of H2S 
inhibition. In summary, the discrepancies between the hepatic response to PE and ET-1 
suggest that H2S differentially contributes to microcirculatory dysfunction in the systemic 
and hepatic microcirculations. We propose that this is due to H2S exerting a differential 
vasoactive function on presinusoidal and sinusoidal sites within the liver. Moreover, our 
findings suggest that H2S may contribute to the progression of sepsis by contributing to 
microvascular failure.  
3.2 Introduction 
Organ failure is a common complication during sepsis and is associated with an 
increase in morbidity and mortality [78]. Microcirculatory dysfunction is an important 
contributor to organ injury [52]. In most vascular beds, sepsis attenuates vasoconstriction 
in response to catecholamine signaling. This contributes to intractable hypotension, 
inadequate tissue perfusion, and organ dysfunction. The portal venous circulation is also 
hyporesponsive to catecholamine signaling; however, depressed catecholamine signaling 
does not contribute to hepatic microvascular dysfunction [97]. Instead, sinusoidal 
hyperconstriction, due to increased sensitivity to the vasopressor, endothelin-1 (ET-1), 
results in heterogeneous perfusion and focal hypoxia which contributes to hepatic 
dysfunction and ultimately overall injury [12-13, 94].  
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H2S is primarily produced as a byproduct of cysteine metabolism by two 
pyridoxal 5’ phosphate (PLP) dependent enzymes: cystathionine β synthase (CBS) and 
cystathionine γ lyase (CSE) [18, 123]. Additionally, a third PLP independent enzyme, 3 
mercaptopyruvate sulphurtransferase (3MST) synthesizes H2S [114]. CSE is the 
predominant source of H2S in the cardiovascular system and liver [123]. The liver is 
likely exposed to elevated levels of H2S during bacterial peritonitis due to an increase in 
hepatic CSE expression and the arrival of H2S in the portal circulation synthesized from 
by bacteria of the GI tract [144].  
 There are conflicting reports in the literature about the vasoregulatory action of 
H2S [4, 48, 74, 140, 148]. The first indication that H2S modulates the hepatic vasculature 
was reported by Fiorucci et al. Using an isolated perfused liver system, they 
demonstrated that H2S attenuated the increase in portal pressure during infusion of 
norepinephrine (NE) in normal and cirrhotic livers [33]. Therefore, H2S may be 
beneficial during cirrhosis and fibrosis by lowering intrahepatic resistance and reducing 
portal hypertension. Based on this finding, one would predict that elevated levels of H2S 
would prevent sinusoidal constriction during sepsis; however, there is ample evidence 
demonstrating that hepatic dysfunction during sepsis is the result of sinusoidal 
constriction resulting in tissue hypoxia [12-13, 63, 88].  
 The hepatic microcirculation has multiple sites of blood flow regulation. 
Upstream of the sinusoids, terminal portal venules are surrounded by VSMCs and 
respond to vasoactive molecules similarly to other vascular beds. Unlike the capillaries in 
other vascular beds, the hepatic sinusoids can modulate local tissue perfusion by 
changing their resistance which makes them a second, functionally important site of 
50 
 
hepatic perfusion [146]. Unlike portal venules, the sinusoids lack VSMCs. Instead, they 
are surrounded by hepatic stellate cells (HSC) which can modulate perfusion through 
individual sinusoids by altering their contractility in response to vasoactive molecules 
[49, 62]. This unique organization allows regulation of overall hepatic perfusion by pre-
sinusoidal regulatory and spatial distribution of hepatic blood flow within the liver lobule 
[57, 99]. Previous work from our lab has demonstrated that the α1 adrenergic agonist, 
phenylephrine (PE) and ET-1 both increase hepatic vascular resistance [146]. 
Importantly, PE acts only on pre-sinusoidal sites of regulation, whereas ET-1 acts on pre-
sinusoidal and sinusoidal regulatory sites [10-11, 146]. Inflammatory stress primes the 
liver to the vasoconstrictive effect of ET-1 resulting in sinusoidal hyperconstriction and 
tissue hypoxia [13, 107].  
Therefore, the present study was designed to investigate the effect of H2S on the 
different sites in hepatic microvasculature during endotoxemia. Using an isolated 
perfused liver system we investigated the effect of H2S on total intrahepatic resistance 
during portal infusion of PE or ET-1 during endotoxemia. We hypothesize that H2S acts 
as a vasodilator in response to PE, but has no effect on ET-1-induced vasoconstriction, 
particularly during endotoxemia. This study is the first to demonstrate that H2S 
differentially regulates pre-sinusoidal and sinusoidal sites of hepatic perfusion. 
Furthermore, our finding that H2S contributes to systemic vascular hyporesponsiveness, 
but does not affect sinusoidal constriction adds to the current knowledge regarding the 
detrimental effects of H2S on in organ injury during sepsis [144].  
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3.3 Materials and Methods 
Animals: Fifty Male Sprague-Dawley rats (Charles River Laboratories, 
Fayetteville, NC) weighing 272±13.2 g were used in this study. Rats remained 
quarantined for four days following arrival. Rats were maintained in pairs in standard 
cages with bedding with free access to standard rat chow and water in a temperature-
controlled setting under 12-hour light/dark cycles. Rats were removed from the vivarium 
on the morning of the experiment and transported to the laboratory where all surgical 
procedures were performed. Animals were randomly assigned to groups on the day of the 
experiment. All animal manipulation was in strict adherence with National Institutes of 
Health guidelines and experimental protocols were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of North Carolina at Charlotte.  
Materials: Sodium sulfide (Na2S), L-phenylephrine (PE), lipopolysaccharide 
(LPS, Escherichia coli O26:B6), DL-propargylglycine (PAG), were purchased from 
Sigma-Aldrich Co. (St. Louis, MO). Endothelin-1 (ET1) was purchased from American 
Peptide Company (Sunnyvale, CA). 
Isolated Perfused Liver: Isolated, perfused rat livers were used to investigate the 
effect of vasoactive modulators on hepatic portal resistance as described previously [125] 
with modification [89]. Briefly, rats were anesthetized under isoflurane and subjected to 
laparotomy. Heparin (1 USP unit/rat mass (g), Webster Veterinary, Devens, MA) was 
injected into the inferior vena cava. The portal vein was exposed and three loosely tied 
sutures were placed along the length of the vein. The portal vein was cannulated and the 
sutures were tightened to secure the cannula in place. The inferior vena cava and 
abdominal aorta were severed to prevent hypervolemia due to perfusion and to allow for 
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exsanguation. The pleural cavity was opened and a cannula was inserted into the right 
atrium and directed downward in the superior vena cava. The cannula was secured in 
place just below the diaphragm. Lastly, the inferior vena cava was ligated above the renal 
veins to block perfusate flow. This isolates the liver in situ during perfusion with 
oxygenated Kreb’s Henseleit buffer. Temperature of the buffer was maintained at 37° 
Celsius and continuously oxygenated using 95% O2/5% CO2 gas. Following a 20 minute 
stabilization period, increasing cumulative doses of PE (0.05-20 µM) or ET-1 (0.05-1.0 
nM) were infused sequentially in 5 minute intervals. Total intrahepatic resistance was 
determined by monitoring the pressure in the inflow tubing (portal pressure) using a 
Biopac Systems MP100 transducer (Goleta, CA) during constant flow perfusion 
(16ml/kg/min). The H2S donor Na2S (50 µM) was administered in the perfusate during 
ET-1 or PE infusions for certain animal groups. In other experiments, the CSE-inhibitor 
propargylglycine (PAG, 1 mg/kg) was injected intraperitoneally 30 minutes before liver 
isolation to inhibit endogenous H2S production. For the endotoxin model of sepsis, rats 
were given an injection of LPS (1 mg/kg, ip) 6 hours before liver isolation and perfusion. 
Oxygen Monitoring: The amount of O2 extracted by the liver from the perfusate 
was calculated to assess hepatic oxygen consumption. The perfusate PO2 were monitored 
using an oxygen sensitive Clark-type electrode connected to an oxygen monitor (YSI Life 
Sciences, Yellow Springs, Ohio). All measurements were recorded continuously using 
Biopac systems MP 100 transducer and software (Goleta, CA). Calibration of the 
electrode was performed on the daily using distilled water equilibrated with air and 
adjusted for temperature and elevation. The concentration of the inflow perfusate was 
measured was measured immediately prior to and after the experiment. O2 extraction was 
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calculated by as the difference between the inflow perfusate PO2 and outflow perfusate 
PO2.  
Statistical Analysis: The data are presented as means ± standard error (SEM). 
Statistical significance was determined using 2 way ANOVA analysis. Student-Newman-
Keuls post hoc test was used when ANOVA analysis detected significance. Independent 
and repeated measures analysis was used where appropriate. Statistical significance was 
P < 0.05.  
3.4 Results 
Effect of endotoxin on hepatic resistance in response to PE and ET-1: An isolated, 
perfused liver system was utilized to determine the effect of PE and ET-1 on the hepatic 
vasculature during endotoxemia. Baseline portal pressure in control rats was 3.2±1.4 
mmHg. Despite being slightly elevated, there was not a statistically significant effect of 6 
hour LPS treatment (4.5±1.6 mmHg, P=0.076). PE infusion produced an increase in 
portal pressure with a maximal increase of 5.5±0.8 mmHg with infusion of 20μM PE in 
control animals (Figure 15). LPS treatment significantly attenuated the increase in portal 
pressure due to PE infusion with a maximal increase in portal pressure of 4.1±1.0 mmHg 
(P<0.001, Figure 15). LPS treatment had the opposite effect on the vasculature response 
to ET-infusion. LPS potentiated the increase in portal pressure during ET-1 infusion 
(P<0.001, Figure 16). Additionally, LPS caused a significantly greater maximal increase 
in portal pressure (15.2±1.1 mmHg in control vs. 18.7±2.3 mmHg in LPS, P<0.017).  
Effect of H2S on hepatic resistance in response to PE and ET-1: To determine the 
effects of hydrogen sulfide on hepatic resistance, isolated livers were perfused with 
Kreb’s buffer or Kreb’s buffer containing the H2S donor Na2S (50 μM). H2S did not 
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significantly affect the resting portal pressure (4.1±2.7 mmHg vs. 3.2±1.4 mmHg in 
controls, P=NS). H2S treatment significantly reduced the dose dependent increases in 
portal pressure during PE infusions (Figure 17, P=0.01). H2S had no effect on the 
increase in portal pressure during infusion of ET-1 (Figure 18). 
 Effect of combined H2S/LPS treatment on hepatic resistance in response to PE 
and ET-1: LPS treatment followed by perfusion with 50 μM H2S Kreb’s buffer did not 
affect the resting portal pressure (4.2±0.5 mmHg). Infusion of 5μM PE increased portal 
pressure 5.4±0.5 mmHg (Figure 19). LPS and H2S each reduced this response to 3.3±0.5 
and 3.1±.4 mmHg respectively (P<0.05). A synergistic interaction between LPS and H2S 
produced a nearly complete attenuation of the increase in portal pressure during 5μM PE 
infusion (1.6±0.5 mmHg increase in H2S/LPS P<0.05). Infusion of 0.5 nM ET-1 
increased portal pressure by 13.6±1.0 mmHg in control rats (Figure 20). This effect was 
significantly increased in LPS-treated rats (19.3±1.3 mmHg increase, P<0.01). H2S had 
no effect on the increase in portal pressure in neither control nor LPS-treated rats 
(15.0±1.5 and 18.2±1.5 mmHg respectively).  
Effect of inhibition of endogenous H2S synthesis on hepatic resistance during 
endotoxemia: Hepatic synthesis of H2S was inhibited by treating rats with dl-
propargylglycine (PAG) (50mg/kg ip) 30 minutes prior to liver isolation. PAG treatment 
alone had no effect on the resting portal pressure when compared to controls (3.6±0.9 
mmHg vs. 3.2±1.4 mmHg). PAG treatment caused a greater increase in portal pressure 
due to infusion of PE (P<0.001, Figure 21) and ET-1 (P<0.001, Figure 22) when 
compared to control animals. To test the effect of endogenous H2S synthesis during 
endotoxemia, rats were treated for 6 hrs with LPS then given PAG 30 minutes prior to 
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isolation. The combination of PAG and LPS had no effect on baseline portal pressure 
when compared to controls (4.8±0.7 mmHg). Infusion of 5 μM PE resulted in an increase 
in portal pressure of 4.7±0.5 mmHg in controls which was reduced to 3.3±0.6 mmHg in 
LPS-treated rats (P<0.05, Figure 23). PAG treatment reversed the effect of LPS on PE-
induced vasoconstriction during endotoxemia (6.1±0.5 mmHg, P<0.05). An 11.3±0.8 
mmHg increase in portal pressure was observed during infusion of 0.5 nM ET-1 in 
control rats (Figure 24). LPS and PAG treatment both caused a greater increase in portal 
pressure to ET-1 (16.2±1.1 and 15.4±1.3 mmHg respectively, P<0.05). The combination 
of PAG and LPS was not significantly different from LPS or PAG alone (14.7±1.3 
mmHg).  
 Effect of H2S and PAG on O2 consumption during ET-1 infusion. There was no 
difference in resting hepatic O2 consumption between any of the treatment groups prior to 
ET-1 infusion. For livers in H2S treatment groups, the addition of 50 μM Na2S to the 
perfusate increased O2 consumption (7% over baseline, P<0.05) which was used as a 
baseline for these groups. In control livers, infusion of 0.05 nM ET-1 produced a modest, 
but repeatable increase in O2 consumption (6% increase over baseline, P<0.05). In livers 
isolated from LPS-treated rats, infusion of 0.05 nM demonstrated a trend towards 
decreased oxygen consumption, but it was not statistically significant (100% vs. 92 %, 
P=0.058). However, hepatic O2 consumption during infusion of 0.05 nM ET-1 was 
significantly lower in the LPS group when compared to controls (90 % vs. 106 %, 
P<0.05). The H2S group and H2S/LPS group were not significantly different from either 
the control or LPS groups during infusion of 0.05 nM ET-1 (Figure 25, 99% of baseline 
and 98% of baseline, respectively). PAG treatment was significantly lower than controls 
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during 0.05 nM ET-1 infusion (P<0.05, Figure 26). While PAG appeared to restore O2 
consumption in LPS-treated animals, the results were not statistically significant 
(P=0.055). When the concentration of ET-1 was increased to 1 nM, hepatic O2 
consumption was significantly reduced in all treatment groups (P<0.001). 2 way ANOVA 
analysis demonstrated a significant effect of H2S on hepatic O2 consumption which was 
increased over control and LPS treatment groups. PAG and PAG/LPS treatment groups 
were reduced during infusion of 1 nM ET-1 similar to control and LPS groups and no 
significant differences were observed.  
3.5 Discussion 
The role of H2S in disease and inflammation is the source of considerable debate. 
H2S prevents myocardial and hepatic ischemia/reperfusion injury which is partially the 
result of an increase in cellular antioxidant capacity via induction of antioxidant gene 
expression [59, 117]. On the contrary, inhibition of endogenous H2S synthesis 
significantly reduces organ injury and improves survival in septic mice by attenuating the 
inflammatory response [72, 144]. In the earliest stages of sepsis, hepatocellular injury is 
initially the result of excessive cytokine release from kupffer cells (KCs) [6, 134]; 
however, it is now well established that continued hepatocellular dysfunction is primarily 
the result of hepatic microvascular failure, particularly in the sinusoids [12-13, 63, 94]. 
As a vasoregulatory molecule that is elevated in the liver during sepsis [144], it is 
possible that H2S contributes to the dysregulation of hepatic sinusoidal perfusion.  
  Fiorucci et al were the first to demonstrate a vasoregulatory role of H2S in the 
hepatic microcirculation. In their study, H2S attenuated the increase in intrahepatic 
resistance to norepinephrine (NE) in normal and cirrhotic rats. This vasodilatory effect 
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would likely be beneficial during chronic conditions, like cirrhosis, by decreasing 
intrahepatic resistance and attenuating portal hypertension [72]. If H2S acts as a 
vasodilator in the hepatic microcirculation, one would predict that H2S could also be 
beneficial during sepsis via improved tissue perfusion. The hepatic microcirculation is 
regulated at presinusoidal and sinusoidal sites [90]. Therefore, we tested the effect of H2S 
on the vascular response to phenylephrine and endothelin-1 that act at these sites, 
respectively, in an endotoxin model of sepsis. Our study demonstrates that H2S 
differentially modulates the response of the hepatic microcirculation to vasopressor 
which suggests that H2S may exert a different vasoregulatory function at different sites 
within the liver. Moreover, our results highlight the complex role H2S serves in 
modulating the microcirculation during endotoxemia.  
Several factors contribute to systemic microcirculatory dysfunction during sepsis, 
including activation of pro-coagulant pathways, recruitment of leucocytes, and excess 
production of vasoactive agents [52]. In healthy individuals, the activation of α1 
adrenergic receptors by circulating catecholamines causes vascular smooth muscle cell 
contraction and reduces blood flow through the vascular bed which allows for the spatial 
distribution of cardiac output. During sepsis, the excessive release of vasodilators 
suppresses the response of the endothelium to catecholamines [97]. The diffuse 
peripheral vasodilation contributes to systemic hypotension and organ dysfunction [47].  
In this study, we first investigated the effect of H2S on pre-sinusoidal portal 
venules which respond to catecholamines in a similar manner to systemic resistance 
vessels. Evidence to support this was provided by studies demonstrating decreased 
vascular responsiveness to phenylephrine in livers isolated from endotoxemic rats. 
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Moreover, administration of an inhibitor of NOS reversed the hyporesponsive of the 
hepatic vasculature suggesting the importance of increased production of vasodilatory gas 
NO in vascular hyporesponsiveness [97]. Like NO, H2S acts as a vasodilator which 
suggests that a similar effect of H2S should occur during endotoxemia [48]. Infusion of 
increasing doses of PE produced a dose dependent increase in portal pressure in isolated 
livers, which was significantly diminished in livers isolated from LPS-treated rats. The 
addition of exogenous H2S (50μM) to the perfusate almost completely abrogated the 
increase in portal pressure in response to PE in livers isolated from endotoxemic rats 
suggesting a synergistic effect of LPS and H2S. 
We used the suicide inhibitor of CSE to block hepatic H2S synthesis during 
endotoxemia to determine if endogenous H2S production contributes to vascular 
hyporesponsiveness. PAG treatment alone significantly potentiated the increase in 
intrahepatic resistance in response to PE, suggesting that H2S is involved in the constant 
regulation of hepatic blood flow. Importantly, PAG treatment reversed the 
hyporesponsiveness of the presinusoidal venules to PE during endotoxemia.  
Given that the only target of PE in the hepatic microcirculation are pre-sinusoidal 
resistance vessels [146], the previous results suggest that H2S is involved in the 
modulation of hepatic microvasculature at the level of portal terminal venules. Because 
the liver is the largest internal organ and a major recipient of cardiac output, excessive 
hepatic vasodilation could potentially contribute to systemic hypotension during sepsis. 
H2S derived from CSE is an important regulator of systemic blood pressure [140]. Since 
portal venules and systemic arterioles are regulated in a similar manner by vascular 
smooth muscle cells (VSMCs), it is likely that H2S contributes to hyporesponsiveness of 
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resistance vessels in most tissues. In support of this hypothesis, circulating H2S levels in 
septic rats have been shown to be negatively correlated to blood pressure [50].  
  Based on our results, PAG treatment may provide a protective effect during sepsis 
by attenuating systemic vascular hyporesponsiveness to catecholamines; however, its 
effect in the hepatic sinusoid remains unclear. Previously, we showed that sinusoidal tone 
is modulated by hepatic stellate cells (HSCs) which contract in response to ET-1 [146]. 
HSCs are activated following inflammatory stress which enhances their contractility to 
ET-1 [107]. The priming effect of LPS on the HSCs results in sinusoidal 
hyperconstriction which is a main cause of tissue hypoxia and cell death [13]. In support 
of the importance of ET-1 in hepatic dysfunction, elevated ET-1 levels in are highly 
correlated to disease severity in cirrhosis [3]. Thus, the sinusoid is a critical regulatory 
site for hepatic perfusion during sepsis. Previous work from our lab and others 
demonstrated that impaired synthesis of NO contributes to sinusoidal dysfunction [67, 81, 
98]. The vasoregulatory effect of H2S in the hepatic sinusoids remains unclear. Therefore, 
we investigated the effect of H2S on the sinusoids which during endotoxemia by 
assessing its effect on ET-1 infusion.  
Infusion of increasing concentrations of ET-1 resulted in progressive increase in 
portal pressure. In agreement with our previous reports, the effect of ET-1 was 
significantly potentiated by endotoxin treatment. Based on its vasodilatory action, we 
hypothesized that H2S would attenuate the hypersensitization of the hepatic sinusoid to 
ET-1 during endotoxemia. Surprisingly, we observed no effect of H2S on ET-1-induced 
vasoconstriction in neither control nor endotoxin treated rats. Interestingly, PAG 
treatment increased the vascular response to ET-1 in control livers, but had no effect in 
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the endotoxin group. These results suggest that H2S differentially modulates the vascular 
response to ET-1 when compared to PE.  
This differential effect may be due to the cells responsible for modulating lumenal 
diameter. Portal terminal venules, as well as arterioles, are modulated by VSMCs. The 
vasodilatory effect of H2S is primarily the result of VSMC hyperpolarization via 
activation of KATP channels [103, 128, 148]. Hepatic sinusoidal resistance is regulated by 
HSCs which may be differentially regulated by H2S. It has been suggested that the H2S 
donor (NaHS) can prevent HSC contraction [30]. However, that study was performed in 
isolated HSCs over the course of 18 hours with NaHS. The spontaneous activation of 
HSCs following isolation may not reflect actual in vivo conditions [130]. Furthermore, 
NaHS rapidly releases H2S which if not contained in a closed system rapidly escapes 
culture media and enters the atmosphere in a short period of time during incubation [71]. 
While the finding of that study is promising, more conclusive research is needed to assess 
the effect of H2S on HSCs.  
 One drawback of our isolated, perfused liver system is that we are assessing total 
intrahepatic resistance by monitoring changing in pressure during constant flow 
perfusion. An anticipated consequence of this is that the vasoconstriction at one location 
can be counteracted by vasodilation at another location. The suppression of a response 
during PE clearly demonstrates a vasodilatory effect of H2S; however the lack of an 
effect during ET-1 infusion may be due to a set of more complex vascular events. It is 
possible that H2S can induce vasoconstriction in the hepatic sinusoid which lack VSMCs 
and vasodilation at presinusoidal sites.  
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While H2S is generally regarded as a vasodilator, there are several reports that it 
can function as a vasoconstrictor. In VSMCs, H2S has been shown to lower cAMP levels 
and inhibit contraction [74]. H2S could increase the sensitivity to ET-1 by lowering 
cAMP levels in HSCs. cAMP has been shown to desensitize ETA receptors on HSCs to 
ET-1 [104]. A second mechanism, reported by Ali et al, demonstrated that high doses of 
exogenous H2S produce hypotension, whereas low dose intravenous infusion of the H2S 
donor, NaSH, produced a transient increase in mean arterial pressure in rats [4]. 
Interestingly, no increase in MAP was observed following treatment with L-NAME, a 
NOS inhibitor suggesting an interaction between the two gasses. It has been proposed 
that H2S may interact with NO to form a vasoinactive nitrosthiol thereby quenching the 
nitric oxide signal [137]. This could be of particular interest in endotoxemia as ET-1 
stimulated NO synthesis in SECs is diminished [67]. It is possible in our study that the 
addition of exogenous H2S may quench NO availability causing constriction in the 
sinusoids while also hyperpolarizing VSMCs in the terminal portal venules resulting in 
not net change in intrahepatic resistance.  
Previously, we reported that H2S potentiates the increase in O2 consumption 
induced by PE infusion which may contribute to hypoxic stress [89]. ET-1 stimulates 
glycongenolysis and O2 consumption in isolated rat hepatocytes [111, 146]. Therefore, 
we investigated the effect of H2S and PAG on ET-1 stimulated O2 consumption. Infusion 
of low concentrations of ET-1, which did not produce a vascular response, increase 
hepatic O2 consumption in control livers. At higher doses of ET-1, O2 consumption was 
significantly reduced to the excessive vasoconstriction of the sinusoids. Hepatic O2 
consumption was significantly reduced by LPS treatment most likely due to enhanced 
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sinusoidal vasoconstriction. This finding highlights the importance of sinusoidal integrity 
in maintaining proper O2 delivery during endotoxemia. The addition of H2S to the 
perfusate caused an initial increase in O2 consumption due to hepatic oxidation of H2S. 
While H2S had no effect in control or LPS livers during 0.5 nM ET-1 infusion, it was 
associated with a significant increase in O2 consumption at the highest dose of ET-1. 
Throughout the experiment, H2S was undetectable in outflow perfusate indicating 
complete hepatic H2S oxidation. Despite the decreased O2 consumption during sinusoidal 
hyperconstriction, the liver still utilized O2 for H2S oxidation providing further evidence 
that H2S oxidation may contribute to hypoxic stress during endotoxemia. We observed 
that PAG potentiated the vascular effect of ET-1, in agreement with this hepatic O2 
consumption was significantly reduced compared to controls during low dose infusion of 
ET-1. While the PAG results in LPS-treated animals were not statistically significant 
(P=.055), there was a trend toward restoring hepatic O2 consumption to baseline levels. 
Since the reduction in O2 consumption in LPS-treated animals is the result of sinusoidal 
constriction it is tempting to speculate that PAG treatment may improve sinusoidal 
perfusion during endotoxemia.  
  The present study sought to investigate the effect of H2S on different regulatory 
sites in the hepatic microcirculation. Using an isolated, perfused organ system, we 
demonstrated a differential effect of H2S on sites presinusoidal resistance vessels that 
respond to PE and the sinusoids which are modulated primarily by ET-1. We conclude 
that H2S contributes to the loss of vasomotor control in resistance vessels subject to 
regulation via catecholamine signaling. While we cannot conclude that H2S causes 
vasoconstriction in the sinusoids, we do demonstrate that there is no attenuation of ET-1 
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hypersensitization, suggesting differential regulation in the sinusoids. Additionally, we 
show that hepatic oxidation occurs despite limited O2 availability due to sinusoidal 
hyperconstriction. This finding combined with our previous report that H2S lowers 
hepatic oxygen availability in vivo supports the hypothesis that elevated H2S levels may 
exacerbate hepatic tissue hypoxia. The discrepancy between the effects of H2S on PE and 
ET-1 demonstrate the need for a better understanding of H2S as a vascular modulator. 
Overall, our study demonstrates that the regulation of hepatic vascular tone by H2S is 
complex and likely an important modulator in microvascular dysfunction during 
endotoxemia.  
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Figure 15: LPS attenuates the hepatic vascular response to phenylephrine. Isolated,  
perfused livers from control rats or rats treated for 6 hours with LPS (1mg/kg ip)  
were subjected to increasing doses of PE. Portal pressure was monitored during  
constant flow perfusion with Kreb’s buffer. LPS attenuated the dose dependent increase  
in portal pressure caused by PE (P<0.001). Data is presented as the mean increase in  
portal pressure over baseline ± SEM and compared using two way ANOVA with  
SNK post hoc test. N=4 in control group, N=5 in LPS group. 
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Figure 16: LPS potentiates the hepatic vascular response to endothelin-1. Isolated, 
perfused livers from control rats or rats treated for 6 hours with LPS (1mg/kg ip) were 
subjected to increasing doses of ET-1. Portal pressure was monitored during constant 
flow perfusion with Kreb’s buffer. LPS potentiates the increase in portal pressure caused 
by ET-1 (P<0.001). Data is presented as the mean increase in portal pressure over 
baseline ± SEM and compared using two way ANOVA with SNK post hoc test. N=7 in 
control group, N=4 in H2S group. 
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Figure 17: H2S attenuates the increase in portal pressure caused by PE. Isolated,  
perfused livers were perfused at a constant flow rate with control buffer or buffer  
containing 50 μM Na2S. H2S attenuates PE-induced increases in portal pressure  
(P>0.001). Data is presented as the mean increase in portal pressure over baseline ± SEM 
and compared using two way ANOVA with SNK post hoc test. N=4 in control group, 
N=6 in H2S group.  
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Figure 18: H2S has no effect on the increase in portal pressure caused by ET-1.  
Isolated, perfused livers were perfused at a constant flow rate with control buffer or  
buffer containing 50 μM Na2S. H2S has no effect on ET-1 mediated increases in portal  
pressure (P=NS). Data is presented as the mean increase in portal pressure over baseline  
± SEM (3-6 rats per group) and compared using two way ANOVA with SNK post hoc  
test. N=7 in control group, N=3 in H2S group. 
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Figure 19: H2S potentiates LPS-induced vascular hypo-responsiveness to PE. Livers 
 isolated from control and endotoxemic rats were perfused with control or 50 μM H2S  
Kreb’s buffer. Graph shows mean increase in portal pressure (mmHg) during infusion of  
10 μM PE. Data is presented as mean ± SEM and compared using two way ANOVA  
with SNK post hoc test. * P<0.05 compared to control. # P<0.05 compared to  
LPS and H2S. N=4 in control group, N=5 in LPS and H2S/LPS group, N=6 in H2S group. 
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Figure 20: H2S does not affect LPS-induced vascular hyper-responsiveness to ET-1. 
Livers isolated from control and endotoxemic rats were perfused with control Kreb’s 
buffer. Graph shows mean increase in portal pressure (mmHg) during infusion of .5 nM 
ET-1. Data is presented as mean ± SEM and compared using two way ANOVA with 
SNK post hoc test. * P<0.05 compared to control. N=7 in control group, N=4 in LPS 
group, N=3 in H2S and H2S/LPS groups. 
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Figure 21: PAG treatment increases sensitivity of the hepatic vasculature to PE. 30 
minutes prior to liver isolation rats were treated with CSE inhibitor PAG (50mg/kg ip).  
PAG potentiates the increase in portal pressure during infusion of PE (P<0.001). Data is 
presented as mean ± SEM and compared using two way ANOVA with SNK post hoc 
test. N=4 in control group, N=3 in PAG group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 0.05 0.1 0.5 1 5 10 20
In
c
re
a
s
e
 i
n
 P
o
rt
a
l 
P
re
s
s
u
re
(m
m
H
g
)
0
2
4
6
8
10
12
Control 
PAG 
[Phenylephrine] (M)
* *
*
*
*
*
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: PAG treatment increases sensitivity of the hepatic vasculature to ET-1. 30  
minutes prior to liver isolation rats were treated with CSE inhibitor PAG (50mg/kg ip). 
PAG potentiates the increase in portal pressure during infusion of ET-1 (P<0.001). Data 
is presented as mean ± SEM and compared using two way ANOVA with SNK post hoc 
test. N=7 in control group, N=3 in PAG group 
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Figure 23: PAG treatment reverses hepatic vascular hypo-responsiveness to PE  
during endotoxemia. Control and endotoxemic rats were treated with PAG (50mg/kg)  
30 minutes prior to liver isolation. Mean increase in portal pressure (mmHg) during  
infusion of 10 μM PE. Data is presented as mean ± SEM and compared using two way  
ANOVA with SNK post hoc test. * P<0.05 compared to control. # P<0.05  
compared to LPS. N=4 in controls and LPS group, N=3 in PAG and PAG/LPS groups 
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Figure 24: PAG does not potentiate the hepatic vascular response to ET-1 during  
endotoxemia. Control and endotoxemic rats were treated with PAG (50mg/kg) 30  
minutes prior to liver isolation.  Mean increase in portal pressure (mmHg) during  
infusion of 0.5 nM ET-1. Data is presented as mean ± SEM and compared using two  
way ANOVA with SNK post hoc test. * P<0.05 compared to control. N=7 in control  
group, N=4 in LPS group, N=3 in PAG and PAG/LPS group. 
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Figure 25: Effect of H2S on hepatic O2 consumption in control and endotoxemic  
livers. The PO2 of the outflow and inflow perfusate was monitored to determine hepatic  
O2 consumption during ET-1 infusion. The effect of H2S on hepatic O2 consumption  
during endotoxemia. Data is presented as mean ± SEM and compared using two way  
ANOVA with SNK post hoc test. * P<0.05 compared to control. # P<0.05 compared to  
baseline within each treatment group. 
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Figure 26: Effect of PAG on hepatic O2 consumption in control and endotoxemic  
livers. The PO2 of the outflow and inflow perfusate was monitored to determine hepatic  
O2 consumption during ET-1 infusion. The effect of PAG on hepatic O2 consumption  
during endotoxemia. Data is presented as mean ± SEM and compared using two way  
ANOVA with SNK post hoc test. * P<0.05 compared to control. # P<0.05 compared to  
baseline within each treatment group. 
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CHAPTER 4: HYDROGEN SULFIDE MODULATES SINUSOIDAL 
CONSTRICTION AND CONTRIBUTES TO HEPATIC MICORCIRCULATORY 
DYSFUNCTION DURING ENDOTOXEMIA 
 
 
4.1 Abstract 
Hydrogen sulfide (H2S), is a mediator in the regulation of vascular resistance; 
however, its effect on the hepatic microcirculation has yet to be investigated. The unique 
regulation of hepatic microvascular resistance is perturbed during sepsis which 
contributes to liver injury. Therefore, the present study was designed to determine the 
effect of H2S on the hepatic microcirculation and to determine the contribution of 
endogenous H2S to hepatic microcirculatory dysfunction in an endotoxin model of sepsis. 
We show that portal infusion of H2S is associated with an increase in portal pressure (6.8 
± 0.2 mmHg before H2S vs. 8.6 ± 0.8 mmHg peak during H2S infusion, P<0.05). Using 
intravital microscopy, we observed a reduction in sinusoidal diameter (6.2 ± 0.27 μm 
before H2S vs. 5.7 ± 0.3 μm after H2S, P<0.05) and an increase in sinusoidal 
heterogeneity during H2S infusion (P<.05) suggesting that H2S produces vasoconstriction 
of the hepatic sinusoid. Since hepatic H2S levels are elevated during sepsis, we used the 
cystathionine γ lyase inhibitor (CSE), dl-propargylglycine (PAG), to determine the 
contribution of H2S to the hypersensitization of the sinusoid to the vasoconstrictive effect 
of endothelin-1 (ET-1). Our results show that PAG treatment significantly attenuated the 
hepatic sinusoidal sensitization to ET-1 in endotoxin treated animals. ET-1 infusion 
increased portal pressure to 175% of baseline in endotoxemic animals which was reduced 
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to 143% following PAG treatment (P<0.05). We show that PAG abrogated the increase 
in sinusoidal constriction after ET-1 infusion in LPS treated rats (30.9% reduction in LPS 
rats vs. 11.6% in PAG/LPS rats, P<0.05). Moreover, PAG treatment significantly 
attenuated the increase in NADH fluorescence following ET-1 exposure during 
endotoxemia (61 grey scale units LPS vs. 21 units in PAG/LPS, P<0.05) suggesting an 
improvement in hepatic oxygen availability. This study is the first to demonstrate a 
vasoconstrictive action of H2S on the hepatic sinusoid and provides a possible mechanism 
for the protective effect of PAG treatment reported during sepsis.                
 4.2 Introduction 
Perturbed hepatic sinusoidal perfusion is a critical factor in the development of 
focal tissue hypoxia leading to liver injury during sepsis [12-13, 63]. Sinusoidal blood 
flow is regulated by alterations of vascular tone by extra-sinusoidal resistance vessels, 
consisting of terminal portal venules and hepatic arterioles, and by the sinusoids 
themselves [146]. During sepsis, the excessive systemic production of vasodilatory 
agents, in particular nitric oxide (NO), leads to hyporesponsiveness of the extra-
sinusoidal resistance vessels to the constrictor effect of catecholamines which can 
contribute to diffuse hypotension [97].  However, a local detrimental effect on the liver 
results from sinusoidal hyperconstriction and heterogeneous perfusion during sepsis [13].  
Hepatic sinusoidal tone is regulated mainly by hepatic stellate cells (HSCs) which 
surround individual sinusoids [146]. These contractile pericytes respond to a local 
balance between vasoactive mediators to modulate sinusoidal tone [62]. It is now well 
recognized that liver injury, such as in fibrosis or cirrhosis, leads to HSC 
transdifferentiation of a myofibroblastic phenotype resulting in an increased contraction 
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in response to the vasoactive peptide endothelin-1(ET-1) [107]. However, increased HSC 
contractile response to ET-1 is also observed following a relatively mild inflammatory 
stress such as with low-dose endotoxemia or sepsis [13, 94].  Under normal conditions, 
ET-1 stimulated NO production in sinusoidal endothelial cells (SECs) mitigates the 
constrictor effect of ET-1 [98]. However, inflammatory stress impairs eNOS derived NO 
production in the sinusoidal endothelial cells [67]. The constrictor effect of ET-1 is not 
counteracted by the dilator effect of NO, producing sinusoidal constriction and 
microvascular dysfunction. Furthermore, exacerbation of ET-1 mediated sinusoidal 
constriction during sepsis is associated with an increase in heterogeneous sinusoidal 
perfusion, resulting in a mismatch between O2 supply and cellular demand [13, 57]. 
Inefficient O2 delivery results in the development of focal hypoxia and hepatic injury. 
While it is evident that NO is a significant mediator in sinusoidal tone, it is likely that it is 
not the only contributor to microvascular dysfunction given the plethora of other 
vasoactive molecules present in the hepatic microenvironment. Moreover, although 
exogenous NO donors can restore hepatic microcirculatory function in experimental 
models [41], a beneficial effect remains elusive in clinical trials [77, 121]. Therefore, 
more research regarding the regulation of sinusoidal perfusion is needed to identify other 
potential therapeutic targets.   
The discovery that hydrogen sulfide (H2S) is endogenously synthesized in 
mammals revived interest into the noxious gas typically associated with the smell of 
rotten eggs [135]. Studies show that hepatic H2S synthesis is increased during sepsis and 
endotoxemia [26, 144]. Like NO, H2S acts as a vasodilator [48]. Whereas NO-induced 
vasodilation is cGMP dependent [51], the primary mechanism of vasodilation induced by 
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H2S is via hyperpolarization of VSMCs [148]. The effect of H2S in the liver vasculature 
was first reported by Fiorucci et al. H2S significantly attenuated the increase in 
intrahepatic resistance during norepinephrine (NE) infusion in isolated livers from normal 
and cirrhotic rats [33]. The vasodilatory effect of H2S is likely beneficial during cirrhosis 
by increasing hepatic perfusion and reducing portal hypertension. Based on this finding, 
one would predict that as a vasodilator, H2S would improve hepatic tissue perfusion and 
provide a benefit during sepsis. However, numerous studies have shown that endogenous 
H2S contributes to disease progression in sepsis [5, 72, 144]. 
Recently, we reported that H2S attenuates the pressor effect of phenylephrine (PE) 
in an isolated and perfused liver which is in agreement with the study by Fiorucci et al; 
however, we also showed that H2S has no effect on ET-1-induced increases in portal 
pressure using the same model. Similar to NE, phenylephrine (PE) is known to act on 
extra-sinusoidal resistance vessels only, while ET-1 acts on extra-sinusoidal and 
sinusoidal sites of blood flow regulation [146]. The vasodilatory effect of H2S during PE 
infusion is likely the result of VSMC hyperpolarization in the portal venules. However, 
sinusoidal tone in response to ET-1 is modulated by HSCs, not VSMCs. The finding that 
H2S affects PE, but not ET-1 pressor effects, suggests that the vasoactivity of H2S may be 
different in the hepatic sinusoid compared to the portal venules. Therefore, the present 
study was designed to investigate the vasoregulatory effect of H2S on the hepatic 
sinusoids in vivo. Since H2S has been shown to be deleterious during sepsis, we 
hypothesized that endogenous H2S contributes to the hypersensitization of the hepatic 
sinusoid to ET-1 during sepsis. Using intravital microscopy, we show for the first time 
that infusion of endogenous H2S is associated with net sinusoidal constriction and 
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increased perfusion heterogeneity in normal liver. Moreover, our study demonstrates that 
inhibition of endogenous H2S production significantly reduces hepatic microvascular 
dysfunction in response to ET-1 during endotoxemia which leads to improved O2 
delivery to the tissue. Taken together, our results challenge the notion that H2S solely acts 
as a vasodilator in the liver. Rather, the role of H2S is likely fundamentally different in 
the hepatic sinusoid than it is in most resistance vessels, including the portal venules. 
Furthermore, we provide one possible mechanism for the protective effect of the 
inhibition of endogenous H2S synthesis during sepsis.         
 4.3 Materials and Methods    
Animals: Male Sprague-Dawley rats (Charles River Laboratories, Fayetteville, 
NC) weighing 253 ± 12 grams were used in this study. Rats were housed in a 
temperature-controlled environment on 12-hour light/dark cycles with free access to 
standard chow and water. All animal manipulation was in strict adherence with National 
Institutes of Health guidelines and experimental protocols were approved by Institutional 
Animal Care and Use Committee of the University of North Carolina at Charlotte.  
Reagents: Sodium sulfide (Na2S), DL-progargylglycine (PAG), fluorescein 
Isothiocyanate (FITC) on celite, citrate-phosphate-dextrose with adenine (CPDA) and 
lipopolysaccharide (LPS) (E. Coli, serotype 026:B6) were purchased from Sigma Aldrich 
(St. Louis, Missouri). Endothelin-1 (ET-1) was purchased from the American Peptide 
Company (Sunnyvale, CA). 
Red Blood Cell Labeling: Red blood cells (RBCs) were fluorescently labeled as 
described by Zimmerhackl et al [150]. Briefly, 10-12 ml of whole blood was obtained 
from a donor rat and placed in a tube containing 0.5 ml of heparin (1000 usp units/ml) 
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(J.A. Webster Veterinary Supply, Devens, MA). Blood was centrifuged at 500g for 10 
minutes at 4° Celsius. The plasma supernatant was removed and RBCs were washed 3 
times (500g, 10 min, 4° Celsius) with Alsevier’s buffer (in g/l: 20.5 glucose, 8.0 citric 
acid trisodium salt, 0.55 citric acid, and 3.766 NaCl, pH =6.2) and once in bicine buffer 
(in g/l: 2.264 Bicine, 0.399 NaOH, 7.288 NaCl, pH=8.3). After bicine buffer wash, the 
RBC pellet was resuspended in a 1:1 ratio (50% hematocrit) with bicine buffer. FITC on 
celite (4mg/ml of RBC suspension) was dissolved in Dimethylformamide (100 μl/4 mg 
FITC) and combined with the RBC suspension. After 2 hour incubation with FITC, 
RBCs were washed once with bicine buffer, followed by 3 saline washes. Following the 
final wash, RBCs were resuspended to 50% hematocrit ratio with saline. For storage, 
citrate-phosphate-dextrose with adenine solution (CPDA, 140μl/ml RBC suspension) was 
added to the RBC suspension. Fluorescently labeled RBCs were kept in the dark at 4° 
Celsius and used within 7 days of labeling.  On the day of the experiment, RBCs were 
washed once with bicine buffer and 3 times with saline solution. After the final wash, 
RBCs were resuspended to 50% hematocrit and the RBC suspension (100 µL/100g body 
weight) was injected into the inferior vena cava. 
Intravital Microscopy: Rats were anaesthetized using 1-2% isoflurane (J. A. 
Webster Veterinary Supply, Devens, MA). A laparotomy was performed to expose the 
portal vein and associated vasculature. To prevent splenic congestion, blood flow to the 
spleen was occluded . The splenic vein was isolated and cannulated using a cannula made 
from PE-50 tubing for measurement of portal venous pressure and infusion of test 
substances into the portal vein. The right carotid artery was cannulated in order to 
monitor arterial pressure. Prior to transferring the rat to the microscope, FITC-labeled red 
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blood cells were injected into the inferior vena cava (100 µL/100g body weight at 50% 
hematocrit). 
For microscopy, rats were placed on an Olympus IX70 inverted microscope 
(Olympus America, Melville, NY) and situated on a motorized stage with a viewing 
window over the objective lens. The liver was exteriorized and the left lobe positioned 
over the viewing window to allow for epi-illumination. The internal organs were covered 
with saran wrap and saline-soaked gauze to prevent evaporative loss. The splenic cannula 
was connected to a blood pressure analyzer (Digi-Med low-pressure analyzer; Micro-
Med, Louisville, KY) and a syringe pump (Harvard Apparatus, Holliston, MA) via a t-
tube fitting to allow for simultaneous monitoring of portal pressure (PP) and infusion of 
treatment substances. The carotid cannula was connected to a Digi-Med high-pressure 
analyzer to measure mean arterial pressure (MAP) and heart rate (HR). A MouseOx pulse 
oximeter (Starr Life Sciences, Pittsburgh, PA) was used to monitor arterial oxygen 
saturation and heart rate to ensure the stability of the rat during the experiment. Two 
pericentral and two periportal fields were selected at random and programmed into the 
motorized stage. The motorized stage gives the advantage of repeated imaging of 
multiple fields over several time points. After selecting the four fields, rats were allowed 
to rest for 20 minutes before beginning one of the following experimental protocols. 
H2S Infusion: The H2S donor Na2S was used to investigate the effect of H2S on 
the hepatic microcirculation. In order to determine the effects of infusion, saline was 
infused through the splenic cannula at a rate of 100 µL/min for the first 10 minutes. 
Freshly prepared Na2S (2 µmoles/kg/min) was then infused for 10 minutes, followed by a 
10 minute recovery period of saline. Throughout the experiment, MAP, PP, HR, and O2 
83 
 
saturation levels were monitored and recorded. The sinusoids were visualized using a 
FITC filter (excitation 494 nm, emission 518 nm) and 40x objective lens. Micrographs 
were taken every 10 minutes, with the first set taken at the beginning of the experiment. 
Micrographs were taken using a Cooke Sensicam digital electron multiplier CCD camera 
(The Cooke Corporation, Romulus, MI). 
 Endothelin-1 Infusion: Rats were divided into one of four treatment groups: 1. 
Control, 2. LPS, 3. PAG, 4. PAG/LPS. For the LPS group, rats received an 
intraperitoneal injection of LPS (1 mg/kg) 6 hours prior to surgery. Previous reports from 
our lab indicate that the CSE inhibitor PAG has an effect on the hepatic vasculature 
within 30 minutes of administration. At this early time point, PAG is not expected to 
have an effect on the development of the inflammatory response following LPS 
administration. The PAG group received an intraperitoneal injection of PAG (50 mg/kg) 
30 minutes prior to surgery. For animals receiving both treatments, LPS was injected 5.5 
hours prior to PAG, which was administered 30 minutes before surgery. After the 
stabilization period, saline was infused for ten minutes in order to establish baseline 
readings. ET-1 (125 pmoles/kg/min) was infused for 10 minutes following saline 
infusion. A 30 minute recovery period was allowed after ET-1 infusion, during which 
time, saline was infused to prevent dehydration. Throughout the entire experiment, MAP, 
PP, HR, and O2 saturation levels were monitored and recorded. Micrographs were taken 
every ten minutes, beginning after the start of the first saline infusion. For sinusoidal 
diameter and RBC velocity analysis, digital videos were captured using a FITC filter and 
a 40x objective lens at a frame rate of 15 frames per second for a total of 60 frames. Off 
line analysis was performed using PTI imagemaster software. 
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To assess hepatic oxygen redox potential, lower magnification micrographs (4x 
objective) were collected to assess global NADH autofluorescence (excitation 345 nm, 
emission 455 nm) as previously described [99]. NADH is fluorescent at this wavelength 
while NAD+ is not. An increase in fluorescence intensity correlates with an increase in 
the NADH/NAD+ ratio. This serves as an indirect assessment of oxygen availability. All 
camera settings (gain, binning, black level, contrast) were the same for all NADH 
micrographs. 
Off-line image analysis: Off-line image analysis was performed using PTI 
imagemaster software (Photon Technology International Inc., Birmingham, NJ). For 
sinusoidal diameter and heterogeneity of diameter data, 40x micrographs taken with a 
FITC filter were used. Four vessels were randomly selected per field. Sinusoidal diameter 
was determined by calculating the total area of a vessel and dividing it by the length of 
the vessel (Width = Area/Length). The mean sinusoidal diameter represents the four 
vessels from four different fields per animal. The standard deviation of individual vessels 
within one field was used to assess the heterogeneity of perfusion. Vessel data presented 
is the mean between two different researchers performing independent analysis.  
To assess the percentage of sinusoids perfused, 4 vessels per field were randomly 
chosen. Vessels were considered perfused if blood flow was visible during the 60 
micrograph video, irrespective of flow velocity. The mean sinusoidal perfusion for each 
animal is representative of four vessels from four separate fields. 
 Red Blood Cell Tracking for Velocity Distribution: We developed an 
automated method to detect and track red blood cells during video playback of 
micrograph sequences. To detect red blood cells, a classification model was trained to 
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learn the appearance of red blood cells [1]. For each frame in a given sequence, red blood 
cells were detected based on a set of features that detect the visual differences between 
pixels belonging to cells or the background. These features included mean intensity, 
standard deviation of intensity and the difference between the mean intensity of pixels 
closer to the center of patch and the pixels farther away. Using connected component 
labeling, cell pixels were assigned to cell regions [2]. RBCs were tracked by 
corresponding cell regions in successive frames using a tracking algorithm as previously 
described [3]. For each cell, we dynamically predicted its motion and appearance in the 
next frame. Tracking of cells between frames was based on the best match as determined 
by our prediction model. The number of red blood cells and their velocities were then 
determined from the tracking output of the automated tracking algorithm. For each field 
analyzed, vessels were grouped based upon mean RBC velocities and the distribution of 
velocity speeds was reported. 
Statistical Analysis: All data are presented as means ± standard error of the mean 
(SEM). Statistical analysis was performed using Sigma Plot 11 software (Systat Software 
Inc., San Jose, CA). Statistical significance was determined by one or two way ANOVA 
with independent and repeated measures used where appropriate.  Student-Newman-
Keuls post hoc test was used when statistical differences were detected.  Log 
transformation was performed when data did not pass normality and equal variance tests. 
Statistical significance was set at P<0.05.     
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4.4 Results 
Effect of portal Infusion of H2S on hepatic hemodynamics: We investigated the 
effect of portal infusion of the H2S donor Na2S (2 μmoles/min/kg) on hepatic 
hemodynamics in vivo. H2S infusion increased portal pressure to 8.6 ± 0.8 mmHg from 
6.8 ±0.2 mmHg during baseline saline infusion (Figure 27, P<0.05). After H2S infusion 
was stopped, portal pressure returned to baseline within 10 minutes (6.9 ± 0.2 mmHg). 
Mean arterial pressure (MAP) and heart rate (HR) were monitored to determine the effect 
of H2S infusion on systemic hemodynamics. There was a slight drop in heart rate during 
infusion of H2S (317 ± 11.4 baseline vs. 305 ± 11.7 BPM during H2S infusion, Table 1) 
which persisted through the recovery (302 ± 11.1 BPM). Although this decrease was 
statistically significant (P<0.05), it is not likely to be functionally important. Infusion of 
H2S did not affect MAP when compared to controls (100 ± 4.0 mmHg vs. 102 ± 2.8 
mmHg, Table 1, P=NS); however, there was a small overall drop in MAP at the end of 
the recovery period (96.7 ± 4.6 mmHg, P<0.05) which is likely an effect of the surgical 
procedure.   
Because H2S was acting locally on the hepatic hemodynamics, we used intravital 
microscopy to determine if H2S infusion has an effect on the hepatic sinusoids. H2S 
infusion produced a net decrease in sinusoidal diameter (5.7 ± 0.3 μm after H2S vs. 6.2 ± 
0.3 μm at baseline, Figure 28, P<0.05). 10 minutes after H2S infusion was ceased, 
sinusoidal diameter had nearly returned to baseline (6.0 ± 0.4 μm). Sinusoids adjacent to 
constricted sinusoids have been shown to be dilated following inflammatory stress. 
Therefore, we compared the variability between sinusoidal diameters within each field 
analyzed. One way ANOVA analysis demonstrated a significant effect of treatment over 
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the course of the experiment (Figure 29, P<0.05) suggesting an increase in sinusoidal 
diameter heterogeneity following H2S infusion.  
Effect of PAG treatment on the hepatic microcirculation during endotoxemia: Our 
previous results demonstrated a modest constrictor effect of exogenous H2S on the 
hepatic sinusoid. Since hyperconstriction of the sinusoid is a contributing factor to 
hepatic injury during endotoxemia, we used the non-competitive inhibitor of CSE, dl-
propargylglycine (PAG), to investigate the contribution of endogenous H2S to hepatic 
sinusoidal sensitization to the constrictor effect of ET-1 during endotoxemia. A total of 
twenty rats were divided evenly into four groups; control, LPS (1mg/kg ip, 6 hr), PAG 
(50 mg/kg ip, 30 minutes before microscopy), and cotreatment with LPS/PAG. Systemic 
hemodynamics (MAP and HR) were monitored throughout the experiment and no 
biologically significant changes were observed (Table 2). There was no significant 
difference in baseline portal pressure among the treatment groups. 10 minute infusion of 
ET-1 (125 pmoles/kg/min) resulted in an increase in portal pressure in control rats (121% 
of baseline pressure, Figure 30, P<0.05). While PAG treatment alone had no effect on the 
ET-1 response, the constrictive effect of ET-1 was exacerbated in endotoxemic rats 
(175% of baseline, P<0.01). PAG treatment significantly attenuated the increased 
constrictor effect of ET-1 in endotoxemic animals (143% ± 6.9, P<0.05 compared to LPS 
alone).  
Using intravital microscopy, we demonstrated that infusion of ET-1 reduced 
sinusoidal diameter in control and PAG treated rats by 12.6% and 12.3%, respectively 
(Figure 31). In LPS treated rats, the effect of ET-1 was greatly potentiated (30.9 % 
reduction in diameter, P<0.01 vs. control) similar to our previous reports [12]. Treatment 
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with PAG abrogated the sensitization of the sinusoid to the constrictor effect of ET-1 
resulting in a decrease in sinusoidal diameter similar to controls (11.6 % reduction).  
Since we previously reported the presence of constricted and dilated sinusoids following 
inflammatory stress, we assessed the variability of sinusoidal diameters among treatment 
groups. LPS produced a significant increase in the standard deviation of the means of 
sinusoidal diameters per field (1.9 ± 0.5 μm vs. 0.9 ± 0.2 μm in controls, Figure 32, 
P<0.05) which was attenuated by PAG treatment (0.8 ± 0.1 μm, P<0.05). Interestingly, 
PAG alone produced a significant increase in heterogeneity of sinusoidal diameters 
during ET-1 infusion (1.5 ± 0.3 μm, P<0.05 vs. control). 
There was a clear difference between treatment groups in sinusoidal diameter and 
heterogeneity based on the visual appearance of the sinusoids (Figure 33). We wanted to 
investigate if these physical differences between groups produced functionally important 
alterations in sinusoidal perfusion. To do this, FITC-labeled RBCs were tracked as they 
traveled through individual sinusoids using a computer tracking algorithm we developed.  
For each group, we calculated the mean RBC velocity through individual sinusoids.  
There was no difference between treatment groups prior to ET-1 infusion. While there 
was no statistical difference in the mean velocities of RBC between groups following ET-
1, the distribution of mean sinusoidal RBC velocities was different (Figure 34). The 
distribution of sinusoids with a given RBC velocity followed a standard Gaussian 
distribution in control animals after ET-1 infusion. In LPS treated rats there were a 
greater number of occluded and slow flowing sinusoids distorting the Gaussian 
distribution. PAG treatment restored the distribution of sinusoidal velocities in LPS 
treated rats making it more similar to control animals.           
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The presence of several completely occluded sinusoids following ET-1 infusion 
prompted us to determine the sinusoidal perfusion percentage before and after ET-1 
infusion in each group (Figure 35). There was no difference between the groups in the 
percentage of sinusoids perfused (all groups > 90%) prior to infusion of ET-1. ET-1 
infusion caused a decrease in sinusoidal perfusion percentage among all treatment groups 
(Figure 36). In the LPS group, only 63% of the sinusoids were perfused following ET-1 
infusion, which was significantly less than the control group (91% perfused, P<0.001).  
In LPS treated animals, PAG treatment significantly improved sinusoidal perfusion (78% 
perfused, P<0.05) after ET-1 treatment. 
Based on these results, we investigated whether PAG treatment increased oxygen 
delivery to the liver during ET-1 infusion. Using NADH autofluorescence as an indicator 
of cellular redox potential allows for indirect assessment of oxygen availability. NADH 
fluorescence remained unchanged following infusion of ET-1 in control and PAG rats 
(Figure 36). LPS treatment was associated with a significant increase in NADH 
autofluorescence (61 grey scale units vs. 9.6 units in control, Figure 37, P<0.05). PAG 
treatment attenuated the increase in NADH fluorescence following ET-1 infusion in 
endotoxemic rats (21 grey scale unit increase, P<0.05 vs. LPS). 
4.5 Discussion  
 The present study investigated whether hydrogen sulfide (H2S) modulates 
sinusoidal perfusion within the hepatic microcirculation. We show that portal infusion of 
the H2S donor Na2S in vivo causes a modest increase in hepatic resistance which is due in 
part to sinusoidal constriction. Furthermore, we demonstrate that treatment with PAG 
attenuates the hypersensitization of the hepatic sinusoid to the vasoconstrictive effect of 
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ET-1during endotoxemia. Taken together, our results show that H2S affects sinusoidal 
perfusion in a manner distinct from its action in the portal venules and it significantly 
contributes to microvascular dysregulation in endotoxemia. 
Historically consisting of nitric oxide (NO) and carbon (CO), the 
“gasotransmitters” are a group of endogenously synthesized gases that act as mediators in 
a multitude of physiological and pathophysiological functions [135]. The newest 
recognized member of this group, H2S, is primarily produced during cysteine metabolism 
by two pyridoxal 5’ phosphate dependent enzymes, cystathionine β synthase (CBS) and 
cystathionine γ lyase (CSE) with the latter being the major source of H2S in the liver and 
cardiovascular system [18, 48, 123]. Like NO and CO, H2S participates in the regulation 
of the blood flow by modulating vascular resistance. Evidence for H2S-induced 
vasodilation has been provided in several different experimental models, including 
isolated aortic rings and mesenteric artery beds [21, 48]. Whereas NO and CO mediated 
relaxation of VSMCs is cGMP dependent [39, 51], H2S increases the activity of KATP 
channel activity in VSMCs leading to hyperpolarization and relaxation [148]. A common 
criticism regarding in vitro studies with H2S is the large amount of exogenous H2S 
required to induce vasodilation which may not reflect local concentrations in vivo.  
However, CSE-/- mice spontaneously develop hypertension which provides evidence for 
the important contribution of endogenously produced H2S in vasoregulation [140].  
Despite the large body of evidence that demonstrates the vasodilatory action of 
H2S, there are reports that H2S can produce vasoconstriction in certain circumstances. At 
low concentrations, the H2S donor NaHS reverses the relaxation of aortic rings to 
acetylcholine [74]. Acetylcholine vasodilation is NO dependent. Since H2S had only a 
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minor effect in the absence of acetylcholine, it is likely that H2S-induced vasoconstriction 
results from an interaction with NO. This study also suggested an NO independent 
mechanism of vasoconstriction that involves reduction of cAMP levels in the presence of 
NaHS [74]. In vivo studies demonstrate that intravenous infusion of H2S produces a 
small, transient increase in blood pressure which is abrogated in mice treated with L-
NAME, an inhibitor of nitric oxide synthase (NOS) [4]. Thus, the interaction between 
NO and H2S is likely complex. H2S can directly inhibit all three isoforms of recombinant 
NOS [65-66]; however, reports also show an increase in eNOS activity from H2S 
treatment in bovine arterial endothelial cells (BAECs) [102]. In addition to an effect on 
NOS, H2S may interact with NO to form a vaso-inactive nitrosothiol, quenching the NO 
signal [137]. Due to the ambiguous vasoactive role of H2S in vasoregulation, we first 
investigated the effect of portal infusion of H2S on hepatic vascular resistance in vivo.   
Infusion of the H2S donor Na2S produced a modest increase in portal pressure.  
Previously, we demonstrated that the liver has a high capacity to metabolize H2S [89].  
Since we infused H2S directly into the portal circulation via the splenic vein, it is 
expected that H2S would have no effect on systemic hemodynamics as all should be 
metabolized in a single pass through the liver. Fluctuations in portal pressure result from 
alterations in either splanchnic blood flow or a change in intrahepatic resistance. Since 
portal infusion of H2S should have no effect on splanchnic blood flow, the change in 
portal pressure is most likely due to an increase in intrahepatic resistance. Using intravital 
microscopy, we observed a reduction in sinusoidal diameter during infusion of H2S.  
Kamoun et al reported that ET-1 stimulated sinusoidal constriction produces 
heterogeneous blood flow at the level of individual sinusoids [57]. In our study, H2S 
92 
 
infusion increased the heterogeneity of sinusoidal diameters indicative of increased 
heterogeneity of flow. These findings imply that the increase in portal pressure observed 
during infusion of H2S is the result of increased intrahepatic resistance resulting from 
modest net sinusoidal constriction. 
The finding that H2S causes constriction of the sinusoids suggests a 
fundamentally different mechanism of vascular tone regulation in the sinusoid compared 
to other resistance vessels. H2S hyperpolarizes vascular smooth muscles cells (VSMC) 
via activation of the KATP channel which leads to relaxation and vasodilation [128].  
Importantly, H2S-induced vasodilation is reversible with treatment of the KATP channel 
inhibitor, glibenclamide [148]. Within the liver, VSMCs are present around the portal 
terminal venules and hepatic arterioles. Accordingly, studies have shown that H2S 
attenuates norepinephrine (NE) induced vasoconstriction in isolated livers and increases 
the hepatic arterial buffer response (HABF) [33, 115]. However, these findings suggest 
that H2S acts as a vasodilator in the liver at sites where VSMCs are present. The hepatic 
sinusoids lack VSMCs. Rather, sinusoidal tone is primarily regulated by hepatic stellate 
cells (HSCs). These specialized pericytes surround individual sinusoids and respond to 
local balances between vasodilators and vasoconstrictors [62]. An imbalance between 
vasoactive molecules can cause HSC contraction or relaxation and alter sinusoidal tone.  
During sepsis, an imbalance between NO and the vasoconstrictive effect of ET-1 
produces sinusoidal hyperconstriction [12]. In an isolated, perfused liver, Fiorucci et al 
demonstrated that H2S attenuated catecholamine-induced vasoconstriction and may be 
beneficial during cirrhosis by reducing portal hypertension and increasing hepatic 
perfusion [33]. One would predict that the vasodilatory effect of H2S would also be 
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beneficial during sepsis; however, we recently reported that H2S differentially modulates 
the effect of PE and ET-1 in an isolated, perfused liver. It is possible that H2S may have a 
different effect on the hepatic sinusoids than on the portal venules. Since sinusoidal 
hyperconstriction and heterogeneous perfusion contribute to liver injury during sepsis 
[12-13], we hypothesized that the inhibition of the H2S-producing enzyme, CSE, would 
attenuate hepatic sinusoidal dysfunction in an endotoxin model of sepsis.        
In the sinusoid, the vasoconstrictive effect of ET-1 results from an interaction 
with ETA and ETB receptors expressed in hepatic stellate cells (HSCs) [49]. Under 
normal conditions, this vasoconstrictive effect is counteracted by ET-1 interaction with 
ETB receptors in sinusoidal endothelial cells (SECs) which increases eNOS activity [98].  
ET-1 levels increase following inflammatory stress [3, 109]; however, more importantly 
ET-1 stimulated NO production from SECs is impaired, in part, due to an increase in 
caveolin 1 which has been shown to inhibit eNOS activity [67]. This leads to sinusoidal 
hypersensitization to the vasoconstrictive effect of ET-1. A consequence of sinusoidal 
constriction is the development of heterogeneous sinusoidal flow and focal hypoxia [57]. 
Individual constricted sinusoids are under-perfused, resulting in local ischemia, while 
neighboring sinusoids are dilated and over-perfused. While total hepatic blood flow may 
remain constant, the heterogeneous blood flow fails to match O2 supply with demand, 
producing hepatic dysfunction and injury.         
For this study, we used a mild inflammatory stress (LPS 1mg/kg ip, 6 hours) to 
assess the effect of PAG treatment on the early changes in hepatic microcirculation 
during endotoxemia.  There was no effect on systemic hemodynamics at this dose and 
time point (Table 2). Therefore, the results represent a local hepatic effect rather than a 
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consequence of systemic alterations. Despite our prior result that demonstrated an effect 
of intraportal infusion of H2S on the hepatic sinusoid, PAG treatment did not alter the 
hepatic microcirculation before or after ET-1 infusion in control animals. Since the liver 
has a high capacity to metabolize H2S, it is likely that endogenous H2S levels are 
prevented from accumulating to levels sufficient to exert a vasoactive function under 
normal conditions. However, there is an increase in hepatic CSE expression and H2S 
synthesis during sepsis [144]. Therefore, it is possible that elevated H2S levels are 
sufficient to contribute to sinusoidal dysfunction in endotoxemic rats.  
A study by Zhang et al demonstrated that ET-1 causes sinusoidal constriction 
which colocalizes with HSCs [146]. Kamoun and coworkers observed that portal infusion 
of ET-1 increased the heterogeneity of perfusion through the sinusoids [57]. Several 
studies demonstrated that inflammatory stress, including sepsis, enhances the 
vasoconstrictive effect of ET-1 in the hepatic microcirculation [12, 58, 94]. Furthermore, 
Baveja et al demonstrated that sinusoidal hyperconstriction and heterogeneous blood flow 
lead to impaired O2 delivery to hepatic cells resulting in tissue hypoxia and injury [13]. In 
the present study, we demonstrate that endotoxin significantly increases sinusoidal 
constriction and heterogeneity of sinusoidal perfusion. Additionally, there were more 
non-perfused sinusoids in LPS treated rats following ET-1 infusion when compared to 
control. These effects were reversed by a single injection of PAG 30 minutes prior to 
experimental treatments. In endotoxin treated animals, PAG treatment attenuated 
sinusoidal hyperconstriction and decreased perfusion heterogeneity following ET-1 
infusion. PAG treatment also reduced the number of non-perfused sinusoids after ET-1 
infusion.      
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Since PAG treatment significantly improved microcirculatory function after ET-1 
infusion in LPS treated rats, we investigated if it also improved O2 delivery to the liver 
tissue. Using intravital microscopy, we can exploit the fact that the reduced form of the 
cellular electron carrier, nicotinamide adenine dinucleotide (NADH), is fluorescent when 
excited with UV light, while the oxidized form, NAD+ is not. Because O2 is the final 
electron acceptor in the electron transport chain, a deficiency in O2 will lead to an 
increase in NADH/NAD+. Previous work from our lab demonstrated that hepatic NADH 
autofluorescence is highly correlated to tissue PO2 [99]. Therefore, we can interpret an 
increase in fluorescence as a decrease in hepatic O2 availability. In the present study, 
infusion of ET-1 caused a significant increase in NADH fluorescence in animals treated 
with endotoxin. ET-1 infusion increased NADH fluorescence in all animals with the 
greatest increase occurring in LPS treated rats. In agreement with our sinusoidal 
parameters, PAG treatment reduced the increase in NADH fluorescence in LPS treated 
animals suggesting improved O2 delivery to the hepatic tissue.   
While NADH is an indirect assessment of hepatic O2 availability, our finding is in 
agreement with previous reports from our lab. Using an isolated, perfused liver system, 
we demonstrated that infusion of low concentrations of ET-1 increased O2 consumption 
in control livers. In LPS treated animals, O2 consumption was inhibited by infusion of 
low concentration of ET-1 due to an increase in vascular resistance (presumably 
sinusoidal) and impaired O2 delivery. In endotoxemic livers, PAG treatment restored O2 
consumption following low dose ET-1 treatment. Taken together, our findings suggest 
that PAG maintains O2 delivery to the liver during endotoxemia. 
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Our results demonstrate one possible protective mechanism of CSE inhibition 
during sepsis. It is possible that a portion of the protective effect of PAG occurs 
independently of H2S. However, several other studies show that the protective effect of 
PAG is reversible with treatment with the rapid releasing H2S donor NaHS [5, 143, 145].  
Furthermore, H2S likely does not circulate in the blood; rather, endogenous H2S levels 
are the summation of continuous local production and disposal [92]. Therefore, we 
focused on inhibiting endogenous H2S synthesis to study the effect of H2S during 
endotoxemia because it is more likely to be physiologically relevant than the high 
concentrations of H2S needed to observe in vivo effects.  
Importantly, several studies show a protective effect of PAG pre-treatment on the 
inflammatory response during sepsis [143]. We specifically chose to treat with PAG for 
30 minutes immediately before all microscopy or liver isolation surgery. By 
administering PAG five and a half hours after LPS treatment, we likely mitigate the 
difference in the inflammatory response between the LPS and PAG/LPS groups.  
Therefore, we can interpret our results as the acute effect of the presence of H2S in the 
hepatic sinusoid and not as the consequence of an altered inflammatory response.     
There are conflicting reports of the vasoregulatory actions of H2S in the 
microcirculation. H2S likely provides a beneficial effect during fibrosis and cirrhosis. In 
these chronic conditions, H2S, acting as a vasodilator in the portal venules, likely 
improves hepatic perfusion and reduces portal hypertension. However, during sepsis, the 
failure of the hepatic microcirculation occurs primarily at the level of the sinusoids which 
are hyperconstricted. For the first time, we directly demonstrate an effect of H2S in the 
regulation of sinusoidal tone. The vasoconstrictive effect of H2S in the sinusoids is 
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fundamentally different than the previously reported dilatory effect of H2S in 
presinusoidal resistance vessels. Furthermore, because endotoxemia is associated with 
hepatic sinusoidal hyperconstriction, we investigated if inhibition of CSE significantly 
increases hepatic microcirculatory dysfunction following LPS treatment. We show that 
treatment with the CSE inhibitor, PAG, significantly improves hepatic microcirculatory 
function following ET-1 infusion during endotoxemia. Our results imply that the 
protective effect of PAG observed during sepsis may be due in part to improved hepatic 
perfusion. In summary, our results suggest that the current understanding of the role of 
H2S in the hepatic microcirculation is incomplete. Rather, a more complex role is likely 
where H2S acts as a vasodilatory in the presinusoidal resistance vessels and exerts a 
constrictor effect in the hepatic sinusoids which may contribute to hepatic 
microcirculatory dysfunction during sepsis.     
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Figure 27: Effect of portal infusion of Na2S on portal pressure in vivo. Portal pressure  
was monitored to determine the effect of the H2S donor Na2S on intrahepatic resistance.  
The peak portal pressure during 10 minute infusion Na2S was recorded and compared to  
baseline and 10 minutes following Na2S infusion. Data are presented as the mean ± SEM  
from 5 separate experiments. Statistical analysis was performed using 1 way repeated  
measures ANOVA. * = P<0.05. 
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Table 1: Effect of portal infusion of Na2S on mean arterial pressure (MAP) and  
heart rate (HR). MAP and HR were monitored to determine the systemic effect of portal  
infusion of Na2S. Data are presented as the mean ± SEM from 5 separate experiments.  
Statistical analysis was performed using 1 way repeated measures ANOVA. * = P<0.05. 
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Figure 28: Effect of Na2S on sinusoidal diameter. In vivo micrographs of the hepatic  
sinusoids were taken before, during, and 10 minutes following infusion of H2S donor  
Na2S. Infusion of Na2S decreased sinusoidal diameter. Data are presented as the mean ±  
SEM from 5 separate experiments. Statistical analysis was performed using 1 way  
repeated measures ANOVA. * = P<0.05. 
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Figure 29: Effect of Na2S on heterogeneity of sinusoidal diameters. In vivo  
micrographs of the hepatic sinusoids were taken before, during, and 10 minutes following  
infusion of H2S donor Na2S. Infusion of Na2S decreased sinusoidal diameter. Data are  
presented as the mean ± SEM from 5 separate experiments. Statistical analysis was  
performed using 1 way repeated measures ANOVA and demonstrated a significant  
overall effect of treatment (P<0.05). 
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Table 2: Effect of portal infusion of ET-1 on mean arterial pressure (MAP)  
and heart rate (HR). MAP and HR were monitored to determine the systemic effect of 
portal infusion of ET-1 within treatment groups. Data are presented as the mean ± SEM 
from 5 separate experiments. Statistical analysis was performed using 2 way ANOVA. * 
= P<0.05 compared to baseline within treatment group, # = P<0.05 between treatment 
groups. 
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Figure 30: Effect of dl-propargylglycine (PAG) on portal pressure during infusion of  
endothelin-1 (ET-1) during endotoxemia. Rats were treated with LPS for 6 hours with  
or without PAG treatment 30 minutes before microscopy. Portal pressure was monitored  
during infusion of ET-1. The percent increase over baseline is plotted as the mean ±  
SEM (N=5). Statistical analysis was performed using two way ANOVA with SNK  
post hoc test. * = P<0.05 compared to baseline, # = P<0.05 between LPS and PAG/LPS. 
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Figure 31: Effect of dl-propargylglycine (PAG) on mean sinusoidal diameter  
during infusion of ET-1 during endotoxemia. Rats were treated with LPS for  
6 hours with or without PAG treatment 30 minutes before microscopy. Micrographs of  
sinusoids were taken before, during, and 10 minutes after ET-1 infusion. PAG  
attenuates sinusoidal hyperconstriction following ET-1 infusion during endotoxemia. 
Data are presented as the mean ± SEM from 5 separate experiments. Statistical analysis  
was performed using 2 way ANOVA with SNK post hoc test. * = P<0.05. 
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Figure 32: Effect of dl-propargylglycine (PAG) on sinusoidal diameter heterogeneity  
during infusion of ET-1 during endotoxemia. Rats were treated with LPS for 6 hours  
with or without PAG treatment 30 minutes before microscopy. Micrographs of sinusoids 
were taken before, during, and 10 minutes after ET-1 infusion. PAG reduces the  
heterogeneity of sinusoidal diameter means. Data are presented as the mean ± SEM from  
5 separate experiments. Statistical analysis was performed using 2 way ANOVA with  
SNK post hoc test. * = P<0.05. 
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Figure 33: The effect of ET-1 infusion on the hepatic sinusoids following PAG  
treatment in endotoxemia. Sinusoids were visualized to determine the effect of ET-1  
infusion on LPS-treated rats with or without the CSE inhibitor, dl-propargylglycine  
(PAG). Representative micrographs are shown before and after infusion of 125  
pmoles/kg/min infusion of ET-1.  
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Figure 34: Distribution of sinusoidal flow velocities. The distribution of flow velocities  
through individual sinusoids was determined by tracking FITC –labeled RBCs moving  
through the sinusoids. The distribution of sinusoidal velocities is plotted as the fraction of  
total sinusoids within a given velocity range. A.) Control B.) LPS C.) PAG D.)  
PAG/LPS. 
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Figure 35: Effect of PAG treatment on sinusoidal perfusion percentage following ET- 
1 infusion during endotoxemia. The percentage of perfused sinusoids was determined in  
all treatment group. Data are presented as the mean ± SEM from 5 separate experiments.  
Statistical analysis was performed using 2 way ANOVA with SNK post hoc test.  
* = P<0.05. 
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Figure 36: Effect of PAG treatment on hepatic redox potential following ET-1  
infusion during endotoxemia. NADH autofluorescence was used as an indirect  
assessment of the effect of PAG on hepatic O2 delivery during endotoxemia. An increase  
in fluorescence is correlated to an increase in NADH/NAD+ and indirectly a decrease in  
hepatic O2 content. Data are presented as the mean ± SEM from 5 separate experiments.  
Statistical analysis was performed using 2 way ANOVA with SNK post hoc test.  
* = P<0.05, # = P<0.05 between LPS and PAG/LPS.   
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Figure 37: Representative micrographs of NADH autofluorescence before and after  
ET-1 infusion during endotoxemia. NADH autofluorescence is used as an indirect  
assessment of hepatic O2 availability. An increase in fluorescence is associated with an  
increase in the NADH/NAD+ ratio and indirectly a decrease in hepatic O2 availability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 5: DISCUSSION  
 
 
The role of hydrogen sulfide (H2S) in inflammation and disease is poorly 
understood. Somewhat paradoxically, H2S is cytoprotective following hepatic 
ischemia/reperfusion injury, but contributes to disease progression during sepsis [54, 
144]. It is well established that hepatic dysfunction is a major early complication in sepsis 
[38]. Our lab previously focused on the major contribution of the gasotransmitter, nitric 
oxide (NO), in hepatic dysfunction during sepsis [25]. It is evident that NO has a primary 
role in sepsis; however, the complex septic milieu in the hepatic microenvironment 
suggests a more dynamic pathophysiology. Several studies have reported similarities 
between NO and H2S in the cardiovascular system [135]. While the importance of NO in 
the liver vasculature is well documented, few have investigated the effects of H2S in the 
hepatic microcirculation, particularly following inflammatory stress. Therefore, this 
dissertation focused on the effect of H2S in the liver during sepsis with particular 
emphasis on hepatic O2 availability and microcirculatory dysfunction. 
A combination of endogenous and exogenous H2S results in elevated hepatic 
sulfide exposure during sepsis. Endogenously, cystathionine λ lyase (CSE) is the primary 
source of H2S in the liver [56, 147]. Following endotoxin treatment or cecal ligation and 
puncture (CLP), hepatic CSE levels increase which results in a greater hepatic capacity to 
synthesize H2S [72, 144]. As the major recipient of gastrointestinal blood flow, the liver 
is exposed to an exogenous source of H2S derived from sulfate-reducing bacteria in the 
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gut [15]. During septic peritonitis, it is likely that increased production of H2S from 
intestinal bacteria may enter the portal circulation and increase hepatic sulfide exposure; 
however, the fate of elevated H2S levels in the liver is unclear.  
In the presence of toxic levels of H2S, colonic mucosal cells rapidly detoxify H2S 
generated by colonic bacteria, thereby preventing accumulation [37]. Located in the 
mitochondria, the sulfide quinone reductase (SQR) protein complex couples the oxidation 
of H2S with complex Q of the electron transport chain [68]. The oxidation of H2S by the 
SQR consumes molecular oxygen at a ratio of 1.5 moles of O2 per 1 mole of H2S. In 
isolated mitochondria from chicken livers, H2S oxidation was associated with increased 
O2 consumption and was coupled to ATP synthesis [141]. The relationship between H2S 
oxidation and O2 consumption has also been observed in a recirculating isolated and 
perfused liver [8]. A significant complication during sepsis is the loss of hepatic oxidative 
catabolism of toxic molecules [2, 64]. Whether sepsis affects hepatic sulfide oxidation is 
unknown. Since a diminished capacity to oxidize H2S would be detrimental during the 
high sulfide levels occurring during sepsis, we hypothesized that the liver retains a high 
capacity to metabolize H2S during sepsis in order to prevent toxic hepatic accumulation 
and to remove H2S from the circulation.  
In a non-recirculating isolated and perfused liver, we demonstrate a biphasic 
effect of H2S in the liver, which was not present in an isolated and perfused heart. The 
liver has a high capacity to metabolize H2S until a critical level. Above this threshold, 
toxic amounts of H2S inhibit the oxidation of H2S. H2S clearance from the perfusate was 
associated with an increase in hepatic O2 consumption. When the PO2 of the perfusate 
was reduced, the oxidation of H2S decreased proportionally, suggesting that available O2 
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is obligatory for H2S clearance. Infusion of H2S did not alter total intrahepatic resistance 
indicating that the changes in O2 consumption were not due to a vascular effect.  
In vivo, erythrocytes may participate in the sequestration of H2S via an interaction 
with hemoglobin [43]. It is possible that the lack of RBCs in our experimental settings 
does not reflect hepatic exposure to H2S in vivo. To investigate this possibility, we used 
in vivo microscopy to monitor hepatic oxygen availability during portal infusion of H2S. 
We demonstrated that portal exposure to H2S is associated with a significant decrease in 
hepatic O2 content and redox potential which suggests that elevated H2S in the portal 
circulation is cleared by the liver. Interestingly, in preliminary studies, we were unable to 
detect H2S immediately after it was added to blood. When the same experiment was 
performed with plasma, H2S was detectable, suggesting that RBCs can sequester H2S. 
Nevertheless, our findings clearly demonstrate that H2S in the circulation is available for 
hepatic oxidation which can decrease hepatic O2 availability.  
Early cardiovascular dysfunction during sepsis is characterized by a hyper-
dynamic state. An increase in cardiac output and modest peripheral vasodilation leads to 
an increase in global DO2 [44]. Despite this increase in DO2, it is well established that 
liver dysfunction during sepsis is due in part to hypoxic injury [12, 53, 100]. The findings 
from the first part of this dissertation suggest that H2S may act as a double edged sword 
during sepsis and contributes to hepatic dysfunction resulting from focal hypoxia. The 
presence of elevated hepatic H2S levels would require greater H2S oxidation to prevent 
the toxic effects. As a consequence, H2S oxidation consumes O2, which would exacerbate 
hypoxic stress. The inverse relationship between O2 and H2S oxidation may partially be 
responsible for the increase in hypoxia inducible factor (HIF-1α) during endotoxemia 
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[110]. Indeed, C. Elegans grown in H2S containing medium exhibit elevated levels of 
HIF-1α nuclear accumulation [17]. Since HIF-1α enhances the pro-inflammatory 
response during endotoxemia [75, 100], then it may be involved in the pro-inflammatory 
effects of H2S during sepsis. Moreover, we have shown that as O2 levels fall, H2S 
oxidation is reduced. The development of tissue hypoxia during sepsis would lead to 
decreased H2S oxidation which may allow H2S to accumulate to toxic levels and, 
possibly, enter the systemic circulation and contribute to systemic cardiovascular 
dysfunction.      
The contention that H2S contributes to hepatic hypoxia is muddled because H2S is 
a vasoactive molecule which may affect DO2 [48]. The main vasoregulatory action of 
H2S occurs via activation of KATP channels in vascular smooth muscle cells (VSMCs) 
which leads to relaxation of resistance vessels [148]. The vasodilatory effects of H2S may 
increase hepatic tissue perfusion and O2 delivery which could mitigate the effect of H2S 
oxidation on hepatic O2 levels during sepsis. A vasodilatory effect of H2S on the hepatic 
vasculature was first demonstrated by Fiorucci et al. using livers isolated from normal 
and cirrhotic rats [33]. They found that H2S attenuated the vasopressor effects of 
norepinephrine which was independent of NO. Portal hypertension resulting from an 
increase in intrahepatic resistance is the main complication during chronic conditions like 
fibrosis and cirrhosis [7]. The vasodilatory effect of H2S on the hepatic vasculature would 
be beneficial by decreasing hepatic resistance and attenuating the development of portal 
hypertension. While similarities exist between vascular dysfunction in cirrhosis and 
sepsis, the effect of H2S on hepatic resistance during sepsis has yet to be investigated.  
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 Unlike the systemic circulation, where tissue perfusion is primarily regulated by 
VSMCs surrounding pre-capillary resistance vessels (arterioles), hepatic perfusion is 
regulated at pre-sinusoidal as well as sinusoidal sites [11]. The modulation of pre-
sinusoidal regulatory sites is similar to other vascular beds. In these vessels, vascular 
dysfunction following inflammatory stress is characterized by hyporeactivity to 
catecholamines [97]. Ample evidence suggests that a second functionally important 
regulatory site of hepatic perfusion in the liver is at the level of the sinusoid, particularly 
following inflammatory stress [25, 63, 98, 112]. The primary modulator of sinusoidal 
resistance is the hepatic stellate cell (HSC) [62, 146]. These specialized pericytes contract 
in response to vasoactive molecules including endothelins, eicosanoids, and angiotensin 
II [9, 49, 60]. Inflammatory stress is associated with the activation of HSCs which leads 
to a myofibroblast-like phenotype and enhanced contraction in response to 
vasoconstrictors, particularly endothelin-1 (ET-1) [105, 107]. Moreover, inflammatory 
stress leads to an uncoupling of ET-1/ETB binding and eNOS activation in SECs due, in 
part, to an increase in the inhibitory protein caveolin-1 [67, 81, 113]. The resulting 
imbalance in the antagonistic relationship between vasodilators and vasoconstrictors 
leads to sinusoidal hyperconstriction which is a main cause of increased intrahepatic 
resistance in cirrhosis and sepsis. Therefore, we investigated the effect of H2S on 
intrahepatic vascular responses during infusion of the α1 adrenergic agonist, 
phenylephrine (PE), and ET-1 during sepsis. 
 Infusion of PE or ET-1was associated with an increase in portal pressure in livers 
isolated from control rats, which is indicative of an increase in total intrahepatic 
resistance in isolated livers during constant flow perfusion. An increase in intrahepatic 
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resistance is the summation of changes in resistance at both pre-sinusoidal and sinusoidal 
regulatory sites. Previous work from our lab demonstrated that PE and ET-1 exert their 
vascular effect at different sites [146]. Using in vivo microscopy, portal infusion of ET-1 
resulted in an increase in portal pressure and sinusoidal constriction which colocalized 
with HSCs. While PE infusion increased portal pressure, no effect was observed in the 
sinusoids, suggesting that PE acts only at pre-sinusoidal regulatory sites, while ET-1 acts 
at sinusoidal and pre-sinusoidal sites [146].  
 Since microvascular dysfunction during sepsis occurs at both locations, it is 
important to consider the effects of H2S in the presence of PE and ET-1. In agreement 
with previous studies from our lab, LPS treatment attenuated the vasoconstrictive effect 
of PE, whereas LPS potentiated the vasoconstrictive effect of ET-1 [94, 97]. During 
endotoxemia, VSMCs in portal venules become hyporesponsive to PE due to an increase 
in the production of vasodilatory molecules, such as NO [97]. In agreement with Fiorucci 
et al study, we showed that addition of the vasodilator H2S attenuated the 
vasoconstrictive effect of PE in normal rats and nearly abolished the effect in LPS-treated 
rats. LPS treatment had the opposite effect on ET-1-induced vasoconstriction. The 
hepatic vasculature was hypersensitive to the vasoconstrictive effect of ET-1 during 
endotoxemia; however, we observed no effect of H2S on ET-1-induced vasoconstriction 
in control or LPS-treated livers, suggesting that H2S may not exert a vasoregulatory 
function in the sinusoids.  
 In vitro experiments often require large amounts of exogenous H2S to 
demonstrate a biological effect which may not be reflective of in vivo levels [36, 138]. 
Therefore, we used the inhibitor of CSE, dl-propargylglycine (PAG) [126], to determine 
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the effect of endogenous H2S during PE and ET-1 infusion. PAG treatment 30 minutes 
prior to liver isolation was associated with a significant increase in PE-induced increases 
in portal pressure. In septic and endotoxemic rats, arterial H2S concentration is negatively 
correlated with blood pressure leading to the suggestion that H2S contributes to the 
systemic hypotension [50]. Our findings tend to support this hypothesis and may indicate 
that the inhibition of endogenous H2S has potential as an approach to treat diffuse 
hypotension during sepsis. However, a study by Collin et al showed that PAG treatment 
did not prevent circulatory failure in endotoxemic rats [26]. Interestingly, PAG treatment 
did prevent liver damage, suggesting that the deleterious effect of endogenous H2S during 
sepsis may be liver specific.   
 The effect of PAG treatment on ET-1 infusion is more complex. PAG potentiated 
the effect of ET-1 infusion in control animals; however, PAG had no effect on the 
response to ET-1 in endotoxemic livers. Since ET-1 acts at both presinusoidal and 
sinusoidal sites, the increased sensitivity to ET-1 in control animals may occur at either 
or both sites. Therefore, it is possible that an increase in vascular resistance at pre-
sinusoidal sites by PAG, similar to PE, could be counteracted by the vasodilatory effect 
of PAG in the hepatic sinusoid, resulting in no net change in total intrahepatic resistance.  
In support of this scenario, we observed a significant improvement in O2 
consumption following PAG treatment in LPS-treated rats. ET-1 treatment stimulates 
glycogenolysis in isolated hepatocytes which results in an increase in O2 consumption 
[111]. In our study, infusion of low concentrations of ET-1 caused an increase in O2 
consumption in control livers. At high concentrations, ET-1-induced vasoconstriction 
significantly impairs O2 delivery to hepatic tissue and decreases O2 consumption. In LPS-
118 
 
treated rats, infusion of low concentrations of ET-1 decreases O2 consumption which is 
consistent with a hypersensitization of the hepatic sinusoid to the vasoconstrictive effects 
of ET-1. PAG treatment prevented the decrease in O2 consumption during infusion of low 
concentrations of ET-1 during endotoxemia, suggesting improved sinusoidal perfusion. 
Therefore, we hypothesized that H2S causes sinusoidal constriction and contributes to the 
sensitization of the hepatic sinusoid to the vasoconstrictive effect of ET-1 during 
endotoxemia.  
To test this hypothesis, we used intravital microscopy which allows for the direct 
visualization of the hepatic sinusoids and assessment of sinusoidal perfusion in vivo. 
Portal infusion of H2S was associated with a modest increase in portal pressure and net 
sinusoidal vasoconstriction. Sinusoidal constriction is associated with an increase in 
heterogeneity of sinusoidal perfusion [57]. The increase in sinusoidal heterogeneity is 
characterized by the presence of constricted sinusoids juxtaposed with dilated sinusoids 
producing an increase in the heterogeneity of sinusoidal diameters. Following infusion of 
H2S, there was an increase in the heterogeneity of sinusoidal diameters which is 
consistent with heterogeneous sinusoidal perfusion. Because sinusoidal vasoconstriction 
is a major component of hepatic microcirculatory failure, we investigated whether 
endogenous H2S contributes to the sensitization of the hepatic sinusoid to ET-1 during 
endotoxemia. 
Infusion of ET-1 was associated with a modest increase in portal pressure in 
control animals. The increase in portal pressure was associated with a slight reduction in 
sinusoidal diameter. In LPS-treated rats, the effects of ET-1 were significantly different. 
LPS treatment lead to a greater increase in portal pressure and caused a significantly 
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greater reduction in sinusoidal diameter including several occluded sinusoids. Moreover, 
there was a significant increase in the heterogeneity of sinusoidal diameters. Computer 
automated analyses of RBC flow through the sinusoids confirmed that sinusoidal flow 
heterogeneity was greater in endotoxemic animals compared to controls. PAG treatment 
alone was similar to controls in all aspects except for a greater number of non-perfused 
sinusoids; however, the reasons for this are unclear. PAG treatment 30 minutes 
immediately before microscopy led to a significant improvement in sinusoidal flow 
evidenced by less sinusoidal hyperconstriction, fewer non-perfused sinusoids, and less 
sinusoidal flow heterogeneity following ET-1 infusion. Accordingly, these changes in 
sinusoidal parameters were functionally important. Using NADH autofluorescence to 
assess hepatic O2 availability, ET-1 infusion in LPS-treated animals significantly increase 
NADH fluorescence compared to controls. While PAG treatment had no effect on these 
parameters in control animals, it significantly improved all parameters following ET-1 
infusion during endotoxemia.  
 For the first time, we show that H2S exerts a vasoconstrictive effect on the hepatic 
sinusoid. Currently, the mechanism of H2S-induced vasoconstriction remains unclear, but 
is likely independent of KATP channel activation [74]. In the sinusoid, the vasoconstrictive 
effect of H2S is the result of a shift in the balance between dilators and constrictors which 
regulate HSC contractility. The rapid, transient action of H2S in the sinusoid suggests an 
acute effect. In HSCs, Ca2+ dependent and independent pathways lead to contraction [69, 
101]. The activation of KATP channels by H2S is well documented; however, H2S also 
interacts with calcium channels [85]. Additionally, H2S may modulate the activity ion 
channels via sulfhydration of cysteine residues [86]. H2S has been shown to increase 
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cytosolic [Ca2+] in several cell types, including HUVECs and microglial cells [70, 82].   
Therefore, it is possible that H2S may directly cause HSC contraction via activation of 
Ca2+ channels and increased cytosolic [Ca2+]. 
H2S causes vasoconstriction in isolated aortic rings by inhibiting the accumulation 
of cAMP. In HSCs, the Ca2+ independent pathway, in particular the Rho/ROCK pathway, 
has greater significance on contractility than in smooth muscle cells [61, 120]. 
Accumulation of cAMP inhibits the Rho/ROCK pathway in HSCs and decreases their 
contractility in response to ET-1 [118]. Moreover, the sensitivity of ETA receptors to ET-
1 is decreased after cAMP accumulation [104]. Therefore, H2S may produce 
vasoconstriction in the sinusoid by inhibiting cAMP accumulation in HSCs. 
Our lab has previously focused on the importance of NO in hepatic microvascular 
dysfunction during sepsis. Several studies have demonstrated a complex relationship 
between hydrogen sulfide and NO. In vitro studies show an interaction between H2S and 
NO to form a vasoinactive nitrosothiol. Thus, H2S may cause vasoconstriction via 
reducing the bioavailability of NO. This is an intriguing hypothesis in the septic liver 
where H2S synthesis is increased and impaired NO production contributes to vascular 
dysfunction. Several studies support the involvement of NO in H2S-induced 
vasoconstriction. The relaxation of isolated aortic rings in response to acetylcholine is 
dependent on NO release by an intact endothelium [40]. Treatment with NaHS, an H2S 
donor, attenuates the vasorelaxant effect of acetylcholine. The constrictor effect of H2S is 
lost following removal of the endothelium which suggests an interaction with 
endothelial-derived NO [74]. A similar effect is observed using the H2S precursor, L-
cysteine which attenuates vascular relaxation due to acetylcholine and the nitric oxide 
121 
 
donor, sodium nitroprusside (SNP) [31, 55]. In vivo, the vasopressor effect of H2S 
suggests an increase in peripheral resistance. Moreover, the vasoconstrictive effect of 
H2S appears to be concentration dependent. While high concentrations of H2S cause 
systemic hypotension, intravenous injection of low concentrations of H2S increases mean 
arterial pressure. The vasopressor effect was abrogated by treatment with an inhibitor of 
nitric oxide synthase (NOS) implicating the involvement of NO. A decrease in NO 
bioavailability via an interaction with H2S is likely a mechanism of importance in the 
hepatic sinusoid, particularly during sepsis due to impaired NO production.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
In conclusion, the aim of this dissertation was to investigate the effect of H2S in 
the liver during sepsis. In the first section, we show that the liver is a central regulator of 
H2S levels in the body. Using an isolated, perfused liver, we demonstrated a high 
capacity to oxidize H2S at the expense of cellular O2. The ability to clear H2S from the 
perfusate was dependent on O2 availability and remained a priority during sepsis. 
Furthermore, elevated levels of H2S in the portal circulation decrease hepatic O2 
availability in vivo. In the second section, we show that H2S differentially modulates the 
hepatic response to PE and ET-1, suggesting that H2S may have a differential effect at 
pre-sinusoidal and sinusoidal blood flow regulatory sites. Lastly, in the final section, we 
show for the first time that H2S is a constrictor in the hepatic sinusoid. Moreover, 
endogenous H2S is a major contributor to the hypersensitization of the hepatic sinusoid to 
the constrictor effect of ET-1 during endotoxemia which contributes to tissue hypoxia.  
Taken together, these findings support a deleterious role of H2S during sepsis. We 
propose that the presence of H2S in the liver during sepsis contributes to tissue hypoxia 
and hepatic dysfunction (Figure 38). The elevated levels of H2S would require increased 
sulfide oxidation to prevent toxic accumulation at the expense of hepatic O2. At the same 
time, the vasoconstrictive effect of H2S in the hepatic sinusoid contributes to 
heterogeneous perfusion which impairs O2 and further diminishes hepatic O2 content. The 
resulting tissue hypoxia leads to hepatic dysfunction and cell death. Our study provides 
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evidence of a potential protective mechanism observed following inhibition of 
endogenous H2S in sepsis.  
Despite the findings presented herein, there are still several important questions 
that remain unanswered. The inverse relationship between H2S and O2 suggests that H2S 
may affect the expression of the oxygen sensitive protein, hypoxia inducible factor 1α 
(HIF-1α). The level of HIF-1α is inversely related to cellular O2 tensions [133]. 
Moreover, endotoxin increases HIF-1α in an O2 independent manner and is pro-
inflammatory [100, 110]. Therefore, it is possible that the pro-inflammatory effect of H2S 
during sepsis is due in part to increased expression of HIF-1α. In preliminary experiments 
in mice given a moderate dose of endotoxin (10 mg/kg ip, 6 hr), PAG treatment 
significantly attenuated hepatocellular injury (P<0.01, Figure 39). While not statistically 
significant, PAG treatment demonstrated a trend towards a decrease in HIF-1α levels 
during endotoxemia (Figure 40), but had no effect on iNOS or HO-1 in endotoxemic 
mice (data not shown).   
The effect of H2S during hypoxia is not solely detrimental. In isolated 
hepatocytes, we hypothesized that H2S would sensitize increase hypoxic stress by 
decreasing cellular O2; however, we show that the H2S donor GYY 4137 attenuated cell 
death during hypoxia in part due to a significant reduction in mitochondrial derived 
reactive oxygen species (ROS) (Figure 41). Therefore, further research is needed to 
characterize the effect of H2S in the liver during hypoxia. 
The effect of H2S on NOS is also the subject of debate. In an acellular 
environment, H2S inhibits the activity of all three isoforms of recombinant NOS [65-66]. 
On the contrary, H2S increases NO production from eNOS in bovine arterial endothelial 
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cells suggesting a more complex function in physiological conditions [102]. Preliminary 
experiments from our lab show that Na2S increases eNOS activity and NO levels in 
SECs. However, these results may be unique to the experimental conditions because 
Na2S rapidly releases H2S which escapes to the atmosphere within minutes of incubation 
at 37° Celsius. Therefore, it is important to perform these studies using the slow releasing 
H2S donor GYY 4137. It is possible that H2S may increase eNOS activity, but inhibits the 
accumulation of NO via the creation of a nitrosothiol. The importance of investigating the 
effect of H2S on eNOS activity is underscored by the contribution of impaired eNOS 
activity to hepatic dysfunction during sepsis.  
H2S has shown promise as a potential therapy in several disease states, including 
acetaminophen induced hepatotoxicity, burn injury and ischemia/reperfusion injury 
[127]. Despite these promising findings, evidence suggests that H2S contributes to the 
progression of sepsis. The purpose of this study was to investigate the effect of H2S in the 
liver and its contribution to hepatic tissue hypoxia and microcirculatory dysfunction. The 
importance of these findings is underscored by the fact that sepsis is a common 
complication in several of the diseases that H2S therapy is being proposed. The 
development of potential therapeutics that administers H2S may need to be monitored 
closely to ensure that they do not exacerbate the progression of sepsis in this vulnerable 
patient population. 
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Figure 38:  Proposed mechanism of the deleterious effect of H2S during Sepsis. 
Sepsis increases hepatic exposure to hydrogen sulfide (1).  The increased levels of H2S  
require hepatic oxidation to prevent toxic accumulation. The oxidation of H2S consumes  
molecular oxygen which reduces hepatic oxygen availability (2). Simultaneously, H2S  
contributes to hepatic microvascular dysfunction which impairs hepatic O2 delivery (3). 
The decrease in available oxygen reduces the oxidative capacity of the liver,  
producing a feed-back loop which further increases H2S levels (4).  The final result of  
this pathway is the potentiation of hypoxic stress which contributes to liver dysfunction  
during sepsis (5). 
 
 
 
 
 
 
 
 
126 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Effect of PAG treatment on serum alanine aminotransferase levels 
 during endotoxemia. An intraperitoneal injection of PAG (50 mg/kg) or saline was 
given 30 minutes prior to LPS (10 mg/kg ip) or saline treatment.  After six hours,  
blood was collected and analyzed for the ALT, a marker of hepatocellular injury.  Data  
are presented as the mean ± SEM. Statistical analysis was performed using 2 way  
ANOVA with SNK post hoc test.  
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Figure 40: Effect of PAG treatment on hepatic HIF-1α levels during endotoxemia. 
HIF-1α levels were determined in liver homogenates from mice treated with LPS for 6  
hours with or with PAG pretreatment.  N=4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control LPS PAG PAG/LPS
H
IF
-1

/
 
a
c
ti
n
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
128 
 
 
 
Figure 41: Effect of GYY 4137 on mitochondrial reactive oxygen species  
production in isolated rat hepatocytes during hypoxia. Hepatocytes were incubated 
 under normoxic (20 % O2) or hypoxic ( < 3 % O2) for one hour with or without the H2S  
donor, GYY4137.  Mitochondrial reactive oxygen species production was determined  
using the fluorescent dye MitosoxTM (Molecular Probes, Grand Island, NY). Data are  
presented as means ± SEM of 5 separate experiments.  Statistical analysis was performed  
using 2 way ANOVA with SNK post hoc test. *=P<0.05 vs. control, **=P<0.05 vs.  
Normoxia/GYY & Hypoxia .  
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